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Osteoarthritis (OA) refers to a heterogeneous group of distinct diseases which express a 
common radiographic and clinical phenotype at diarthrodial joints.1,2 It is the leading cause of 
pain and disability in the elderly with a prevalence of 75 percent in the population aged 70 
years.3-5 There is a substantial genetic component in the etiology of osteoarthritis.6-9 It is 
expected that genetic heterogeneity, the extent of which is unknown yet, contributes to a 
spectrum of osteoarthritis related phenotypes. Linkage as well as candidate gene studies are 
being performed to identify the genes involved.10-13 The overall aim of our research project is 
to identify genes that contribute to osteoarthritis. The aim of the present thesis was to 
understand the relation between hemochromatosis and osteoarthritis. As a part of this project, 
candidate osteoarthritis genes were analysed. These include the gene encoding the alpha 
domain of collagen type IX (COL9A1) and the HFE gene involved in hereditary 
hemochromatosis, a disorder that coincides with arthropathy. This thesis, therefore, brings 
together two related complex diseases, that share related phenotypes and possibly some of the 
underlying genetic components. 
The COL9A1 gene encodes the alpha domain of type IX collagen fibrils. In mice, 
knockout or transgenic experiments have shown that the absence of a functional type IX 
collagen fibril leads to cartilage instability and early onset generalized osteoarthritis. In 
humans, a genomewide scan linked the COL9A1 gene, among other loci, to a severe form of 
hip osteoarthritis in women.14 The second candidate gene studied for osteoarthritis is the HFE 
gene in which two common mutations explain type I hereditary hemochromatosis, a common 
disorder of iron metabolism that leads to pathology at multiple organs as well as the joints.15,16 
In fact, arthropathy is one of the most common features of hemochromatosis affecting up to 
80 percent of patients.16 The relation to arthropathy was studied first. These investigations 
have led us to study the implication of the HFE mutations on morbidity and mortality, 
addressing also the issue of penetrance. 
Chapter 2.1 presents a review of the current knowledge on the genetic epidemiology 
of osteoarthritis. It uses osteoarthritis as an example to describe the current strategies in 
unraveling the genetic components of a complex disease. Chapter 2.2 reviews the genetic 
epidemiology of hemochromatosis with special reference to the impact of a common mutation 
on public health and important considerations in population screening. Chapter 3 summarizes 
the results of several association studies. Chapter 3.1 presents the relationship between the 
COL9A1 gene and osteoarthritis and Chapter 3.2 describes the results of an association study 
on the HFE C282Y and H63D mutations with arthralgia, chondrocalcinosis, and 
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osteoarthritis. Chapter 3.3 presents the association between the H63D mutation, Heberden’s 
nodes, with mortality and tests a hypothesis on the role of inflammation in hemochromatosis-
associated arthropathy. Chapter 3.4 describes the relation between HFE mutations, serum 
total bilirubin and mortality, and tests a hypothesis that high levels of serum bilirubin may 
explain, at least in part, the low penetrance of HFE mutations. Chapter 4 addresses the 
heritability estimates for serum iron, ferritin and transferrin saturation. Finally, the findings 
and the future prospects are discussed. 
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Introduction 
Osteoarthritis is a disorder of diarthrodial joints characterized clinically by pain and 
functional limitation, radiographically by osteophytes and joint space narrowing, and 
histopathologically by alterations in cartilage and sub-chondral bone integrity. Osteoarthritis 
has considerable impact on public health in terms of morbidity i.e. productivity, 
hospitalization and prolonged treatment, and it may predict a higher mortality in patients. 
From etiological prospect, osteoarthritis has been shown to be a family of disorders in which 
genetic factors play a central role. Other risk factors include age, gender, weight, 
biomechanical stress, and occupation. Since there is no treatment to prevent or ameliorate the 
underlying disease process, medical interventions are aimed primarily at relieving symptoms 
i.e. pain, preserving joint function and replacing the severely damaged joints. Currently 
efforts are focused on unraveling genetic factors that underlie the pathologic pathways leading 
to osteoarthritis. The genetic studies, as described here, may eventually reveal the underlying 
disease pathways that may provide new targets for intervention. 
Definition and classification of phenotype 
Osteoarthritis can be defined radiographically, clinically or etiologically. The main 
radiographic features used to define osteoarthritis include joint space narrowing, osteophyte 
formation, subchondral sclerosis, cysts and abnormality of bone contour. Most epidemiologic 
studies have used the scoring system described by Kellgren and Lawrence to characterize 
osteoarthritis in the studied population.1 This system scores one of the five grades i.e. 0 to 4 
for osteoarthritis at various joint sites (Table 1). Grading is performed by comparing various 
joint sites i.e. knee, hip, hand and spine with reproductions in a radiographic atlas. A cut-off 
score on the Kellgren and Lawrence scale to diagnose radiographic osteoarthritis is 2. In 
clinical practice, different criteria, based on the presence of joint pain and radiographic 
features are used for a clinical definition of osteoarthritis. The most widely used clinical 
criteria for the definition of osteoarthritis was developed by the American College of 
Rheumatology and are based on pain.2-4 This contrasts with the use of radiographic changes, 
as many subjects do not report pain and the discrepancy depends on the affected joint sites.5 
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Osteoarthritis affects one i.e. monoarticular or multiple joint sites. The pattern of joint 
involvement is influenced by age, gender, race, familial predisposition, previous joint injury, 
presence of metabolic risk factors such as weight and occupational history. When multiple 
joints are affected, there is a stronger association between hand and knee osteoarthritis in 
Caucasian populations.5,6 Generalized osteoarthritis refers to a condition in which Heberden’s 
nodes are found in combination with polyarticular disease.7,8  
Etiologically, osteoarthritis can be defined as primary or secondary. Four main 
categories of disorders can cause secondary osteoarthritis i.e. metabolic disorders such as 
hemochromatosis and chondrocalcinosis, anatomic derangement such as epiphyseal dysplasia, 
major trauma or surgery and inflammatory arthropathy such as rheumatoid arthritis. The term 
inflammatory osteoarthritis is used to identify patients with obvious inflammation and 
multiple joints’ involvement.9 But, in most forms of osteoarthritis, the joints pass through 
phases in which the inflammation is less or more prominent. In inflammatory osteoarthritis, 
some patients develop erosions, an aggressive form of joint destruction,10 which represent the 
end point of the spectrum of disease. Variability in the joint sites and number of sites 
involved, and in etiopathogenesis suggest that osteoarthritis may not represent a single disease 
entity. Osteoarthritis has been defined as a group of overlapping distinct diseases, which may 
have different etiologies but with similar morphologic, and clinical outcomes.2,11 In this 
prospect the articular cartilage degeneration is the ultimate end of several underlying 
pathologic processes.2,11 For genetic studies different osteoarthritis phenotype definitions are 
being used. Primary osteoarthritis is expected to be heterogeneous at the genetic level, 
meaning that different genetic variation predispose to different forms of the disease.12,13 
 
Table 1. Radiographic grading system for osteoarthritis 
Grade Classification Description 
0 Normal No feature of osteoarthritis 
1 Doubtful  Minute osteophyte, doubtful significance 
2 Minimal Definite osteophyte, unimpaired joint space  
3 Moderate Moderate diminution of joint space 
4 Severe Joint space greatly impaired with sclerosis of subchondral bone 
Adapted from the atlas of standard radiographs. Oxford: Blackwell Scientific. 
. 
r  l ssifi ti  s ri ti  
 r l  f t r  f st rt ritis 
 tf l  i t  st t , tf l si ifi  
 i i l fi it  st t , i ir  j i t s   
 r t  r t  i i ti  f j i t s  
 r  J i t s  r tl  i ir  it  s l r sis f s r l  
Adapted from the atlas of standard radiographs. Oxford: Blackwell Scientific. 
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Prevalence 
The prevalence of osteoarthritis has been variously estimated in epidemiologic studies based 
on the inclusion criteria for osteoarthritis: pathological, radiographic or clinical. Pathological 
studies reported that the prevalence of cartilage erosion, subchondral reaction and osteophytes 
are present at the knees of 60 percent of men and 70 percent of women aged 70 years or older. 
Epidemiological surveys based on radiographic findings showed that the prevalence of 
osteoarthritis increases steadily from less than 2 percent in women younger than 45 years of 
age to 30 percent in those aged 45 to 65 years and to 68 percent in those older than 65 years of 
age.14 The Dutch population-based Zoetermeer Study showed that more than 75 percent of 
women aged 60 to 70 years had osteoarthritis hand joints.15 These findings were confirmed in 
another Dutch population-based study, the Rotterdam Study.16 However, when clinical criteria 
are used, the prevalence of symptomatic osteoarthritis drops dramatically from 17 percent 
radiographic osteoarthritis to only 2 percent for knee osteoarthritis in women aged 65 years or 
younger.17,18 This shows a large discrepancy between radiographic and clinical osteoarthritis. 
From this point of view, one may define osteoarthritis, in general, as a silent disease that 
allows the underlying causal process to progress without obvious clinical manifestation and 
thus remains undetected leading to severe irreversible consequences and associated morbidity. 
Risk factors 
There are two groups of factors predisposing to osteoarthritis, factors influencing a 
generalized susceptibility to osteoarthritis such as heredity, obesity, osteoporosis, 
hypermobility and systemic diseases, and factors resulting in a single joint pathology such as 
abnormal biomechanical loading, trauma, joint shape, occupation, and physical activity. Next, 
we will elaborate in detail on the role of hereditary factors in osteoarthritis. 
Evidence for inheritance of osteoarthritis 
In 1941 Stecher19 introduced the possible role of heredity in susceptibility to nodular hand 
osteoarthritis. Later, twin-pair, segregation and population-based studies demonstrated a 
strong hereditary predisposition to generalized osteoarthritis.12,16,19-23 Several studies showed 
that osteoarthritis clusters within families.7,16,20,24,25 Two factors can explain intrafamilial 
clustering of osteoarthritis. First, close relatives inherit the same osteoarthritis predisposing 
DNA variants, and second, they share environmental factors. Twin-pair studies have been 
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used to determine the influence of genetic factors on osteoarthritis at specific joint sites. These 
studies estimated a heritability of 39 to 65 percent for osteoarthritis independent of known 
environmental factors.26-30 Similarly, large population-based family studies confirmed the 
findings of the twin-pair studies with similar heritability estimates for osteoarthritis at hand, 
knee, and hip joints.16,21,22,31,32 Several studies investigated the mechanism by which 
osteoarthritis segregated within families. A large segregation analysis of nuclear families 
suggested a recessive genetic model.21 But, an autosomal dominant mode of inheritance has 
also been reported indicating that different types of mutations/genes influence the 
susceptibility for osteoarthritis.33 Overall, twin-pair and segregation studies revealed a 
substantial genetic component often with a polygenic inheritance for osteoarthritis in 
hand,31,34 knee24 and hip22,24,25,27 joints, which is influenced by environmental factors. At this 
point it is not clear whether genetic heterogeneity underlies the various phenotype definitions 
that are used to establish heritability. 
Genome scans and osteoarthritis susceptibility genes 
The fact that osteoarthritis is heritable raises the question which genes are causal. 
Investigators used two main research tools to identify genes involved in osteoarthritis: 
positional cloning and candidate gene association studies. The evidence for the presence of 
osteoarthritis susceptibility loci has emerged from linkage studies in families with rare 
Mendelian forms of generalized osteoarthritis. In 1994, the first candidate gene for 
osteoarthritis was suggested through the work of Ritvaniemi and colleagues35 who reported 
the type II procollagen gene (COL2A1) is associated to spondyloepiphyseal dysplasia, a mild 
form of generalized osteoarthritis. These and other investigations provided evidence for the 
presence of a disease susceptibility locus for dominant forms of the disease on chromosome 
2q (personal communication, Slagboom PE, 2004), 4q35,36 and 16p.37 Genomewide or 
directed genome screens were also performed for other and milder phenotypes. Linkage 
studies revealed osteoarthritis to be linked to loci on chromosomes 1p,31 2q,38-41 4q12-21,42,43 
6p,44 6q,31 7q,31 9q,31 11q,45-47 13,31 and 16p.37,42 Association studies addressed a large 
numbers of candidate genes, in particular on chromosome 6p and 12q where linkage studies 
failed to identify osteoarthritis predisposing regions. Here we will summarize the overlap in 
linkage in the main osteoarthritis studies that support the relevance of some chromosomal loci 
and candidate genes for different definitions of osteoarthritis. The inclusion criteria and joint 
sites that were investigated in the main studies are shown in Table 2. 
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Two genomewide screens carried out within the Framingham Study suggested a 
linkage to 1p in 296 pedigrees with radiographic hand osteoarthritis.31,34 These studies did not 
find a responsible gene for the observed linkage on this region.31 One of the candidate genes 
located at this region is the Matrilin-1gene. However, a study of siblings with generalized 
osteoarthritis found no linkage to this gene.13 Neither a relationship between the Matrilin-1 
gene and severe hip osteoarthritis was found in the UK cohort of patients with total hip or 
knee replacement.48 However, the Matrilin-1 gene has been associated to radiographic 
osteoarthritis at hip or knee in the population-based Rotterdam Study.49 Overall, the two 
population-based studies, the Framingham Study and the Rotterdam Study, found linkage and 
association to chromosome 1p and the Martilin-1 gene in different osteoarthritis phenotypes: 
radiographic hand and knee45 or hip osteoarthritis.31,34 
Chromosome 2q is the most replicated region implicated in osteoarthritis in both 
linkage and association studies. Chromosome 2q12-13 is linked to distal interphalangeal 
osteoarthritis,41 2q31 to hip osteoarthritis,40 and 2q23-35 to nodal osteoarthritis.38 The 
interleukin-1 gene cluster, mapped on chromosome 2q12-13 has been associated to knee 
osteoarthritis in the UK cohort,50 hip radiographic osteoarthritis in the Rotterdam Study,51 and 
to severe erosive hand osteoarthritis.52 Recently, chromosome 2q13-31 encompassing the 
Frizzled 2B gene that is involved in bone development, has been linked to female hip 
osteoarthritis,23 and to generalized osteoarthritis in the Leiden osteoarthritis cohort (the GARP 
Study) and in the Rotterdam Study (in press). However, others found no linkage of 2q11.2-
36.3 to nodal or knee,53 or hand osteoarthritis.54 These negative findings are supported by the 
Framingham Study.31 Taken together, the findings suggest this region may harbor multiple 
osteoarthritis susceptibility genes. 
Osteoarthritis was also linked to 2p. A two steps genomewide scan recently found a 
significant evidence of linkage of chromosome 2p to hand osteoarthritis in an Icelandic 
population43 that was close to a peak reported earlier in the Framingham Study.31 This region 
coincided with a gene encoding the non-collagenous cartilage extracellular matrix protein, 
Matrilin-3 with missense mutation that cosegregates with hand osteoarthritis in several 
families. This finding is in complement with linkage of the Matrilin-3 region i.e. 2p24-23 to 
multiple epiphyseal dysplasia (MED), a disease associated to osteoarthritis in a genomewide 
scan, as well as in candidate gene studies.55 Two different missense mutations in the exon 
encoding the von Willebrand factor A domain of Matrilin-3 explained MED in two unrelated 
families.55 Overall, there is a substantial repetition for osteoarthritis susceptibility being  
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Table 2. Characteristics of major ongoing osteoarthritis (OA) cohorts around the world. 
Name Ethnicity Study design 
Study population 
(Inclusion criteria) 
Studied 
phenotypes 
Studied 
joints/  
The Framingham 
Heart Study 21,31, 
34,56,57 
American Population-based 
multigenerational 
cohort; began 
1948 
>1300 pedigrees  Radiographic OA 
using K-L ≥2 
Hand, & 
knee 
The Rotterdam 
Study49,51,58-64 
Dutch Population-based 
cohort; began 
1990-1993 
12000 subjects 
aged 55 years or 
over living in 
Rotterdam 
Clinical & 
radiographic OA 
using K-L ≥2 
Hand, 
hip, knee 
& spine / 
The UK OA 
Cohort13,23,39,42,44,48,
50,65,66 
British Sibling-pairs  481 families (1054 
subjects) with ≥2 
affected sibs 
Primary severe 
OA/ THR, or/and 
TKR 
Hip & 
knee 
The Iceland OA 
Cohort43,67,68 
Icelandic Sibling- and 
affected relative 
pairs; began 
1992 
2919 subjects from 
families with ≥2 
affected members 
and 3 first degree 
relatives/unrelated 
controls 
Clinical OA/ 
Patients having 
two HN or 
squaring of 
CMC1 or THR 
Hand & 
hip  
The Leiden OA 
Cohort (GARP)5,69 
Dutch Sibling-pairs; 
nuclear families; 
began 2000 
 Clinical & 
radiographic OA 
Hand, 
hip, knee 
& spine 
Finland Study41 Finnish Twin-pairs Unrelated patients/ 
affected twin pairs 
Clinical & 
radiographic OA 
using K-L ≥2 
Hand 
British National 
Cohort Study70 
British, 
Scottish,  
Population-based 
cohort; began 
1946 
13687 subjects 
born between 
March the 3-9 
1946 
Clinical OA at 
least in 1 joint 
Hand  
Abbreviations: K-L: Kellgren/Lawrence OA scoring system; THR total hip replacement therapy; TKR Total 
knee replacement therapy; FOS Framingham OA scoring system; HN Heberden’s nodes. 
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linked to 2q and 2p regions. 
Although several studies reported a linkage to chromosome 4q, no responsible gene 
for observed linkage has yet been mapped. One study fine mapped the chromosome 4q region 
to a 4 cM interval using a high density of microsatellite markers in female hip osteoarthritis in 
the UK cohort.42 Another study also reported linkage to an 11 cM interval on 4q35 for an 
autosomal dominant form of hip osteoarthritis.36 With respect to hand osteoarthritis, two 
independent genomewide scans have suggested a linkage to chromosome 4q at marker 
D4S2980,43 and 4q26-27.41 No association analysis has been reported. Overall, 4q is likely to 
harbor a common osteoarthritis susceptibility locus for hip and hand osteoarthritis. 
In the interplay of genes for susceptibility to osteoarthritis, chromosome 6 has an 
inarguable position, as it harbors at least two osteoarthritis susceptibility regions namely 
6q12–23.1 and 6p21.3. Each of the two regions harbors at least two known osteoarthritis 
susceptibility loci (Figure 1). When considering the chromosome 6q region, a genomewide 
scan has found a suggestive linkage interval of 50 cM on 6q to a severe form of primary hip 
osteoarthritis in the UK cohort.66 The investigators used several strategies i.e. expanding the 
cohort to higher number of families affected with severe osteoarthritis, genotyping the 
candidate chromosome 6 interval to a higher density, and stratification of the statistical 
analysis by gender, to refine the candidate region to a 11.4 cM female specific interval.66 
Evidence for the role of the COL9A1 gene that encodes the alpha 1 domain of type IX 
collagen polypeptide, a structural protein in cartilage matrix, emerged from different sources. 
Using a two stage linkage analysis of 11 candidate genes following a genome scan, the 
investigators found suggestive evidence for linkage of the COL9A1 8B2 marker to severe hip 
osteoarthritis in 132 concordantly affected female sibling-pairs.71 This group concluded that 
the COL9A1 8B2 marker is in strong linkage disequilibrium with an osteoarthritis 
susceptibility mutation within or close to the COL9A1 gene. Moreover, others reported 
linkage of COL9A1 to multiple epiphyseal dysplasia.72 The other 6q osteoarthritis 
susceptibility gene is the estrogen receptor gene mapped to 6q22.3-23.1. The estrogen 
receptor α gene encodes a protein that is involved in signal transduction pathway. It has been 
associated to radiographic severe osteoarthritis in a young Korean population.73 This finding 
has been replicated in an independent Korean study of patients with knee osteoarthritis.74 In 
the population-based Rotterdam Study, a polymorphism in this gene has been associated with 
knee osteoarthritis in particular with osteophytosis.61 
When considering chromosome 6p21.3, this region has shown a weak evidence of  
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Figure 1.The chromosome 6 osteoarthritis susceptibility loci. 
linkage to female hip osteoarthritis in the UK cohort.71 It harbors at least two osteoarthritis 
susceptibility loci namely the COL11A2 mapped to 6p21.3 and the hereditary 
hemochromatosis gene (HFE) mapped to 6p22.2 (Figure 1). On chromosome 6p21.3, 
COL11A2 has been proposed as a potential hip osteoarthritis susceptibility locus in the UK 
cohort.71 Further, this gene has been associated to autosomal dominant and recessive 
osteochondrodysplasias,75 and implicated in cartilage formation.76 However the role of this 
gene in osteoarthritis at hip as well as other joint locations remains to be confirmed. The other 
candidate locus mapped to 6p21.3 is the HFE gene, which encodes a protein involved in iron 
homeostasis. An abnormal or non-functional HFE protein leads to a form of iron overload 
known as type I hereditary hemochromatosis. The two common C282Y and H63D variants of 
this gene explain type I hereditary hemochromatosis.77 Type 1 hemochromatosis is the most 
common autosomal recessive disorder in Caucasians with a prevalence rate of up to 1 in 200-
400. Arthropathy including arthralgia, osteoarthritis and chondrocalcinosis, is the most 
common early clinical feature in patients with hereditary hemochromatosis,78-81 and occurs in 
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45 percent of symptomatic cases at the time of diagnosis,82 and up to 85 percent of patients 
during the course of the disease.80 Clinically arthropathy presents in hemochromatosis with 
acute inflammation and associated bilateral destruction of metacarpophalangeal joints.80,81 
Hemochromatosis arthropathy includes mainly osteoarthritis like changes at hand, hip and 
knee joints that are more striking at hand metacarpophalangeal joints. Radiographic features 
includes, hook-like osteophytes, joint space narrowing, subchondral cyst formation and 
sclerosis.80,81 These changes may resemble immune related arthropathy such as rheumatoid 
arthritis and may be accompanied by Heberden’s nodes. Chondrocalcinosis is also often seen 
in patients with hemochromatosis, but is usually asymptomatic. Radiographic and histological 
characteristics consist of isolate deposition of calcium crystals in both fibrous and hyaline 
cartilage, i.e. calcium pyrophosphate dihydrate and calcium hydroxiapatite in cartilage at 
knee, hip, symphysis pubis and shoulder joints.80,83 Typical arthritis features strongly suggest 
the diagnosis in the pre-cirrhotic phase when organ damage can still be prevented.82 Although 
linkage studies suggested chromosome 6 as a candidate for osteoarthritis, the evidence for a 
role of the HFE gene in osteoarthritis is still weak, since it is not known whether either or 
both of the common HFE C282Y or H63D variants contribute to increased risk of 
arthropathy. 
The Framingham linkage analysis in 267 families with radiographic hand 
osteoarthritis, suggested a locus for osteoarthritis on chromosome 7q.31,34 This finding was 
replicated by a genome wide scan study of Finnish patients with distal interphalangeal 
osteoarthritis.41 Although this region encompasses several candidate genes for osteoarthritis, 
such as the COL1A2 gene, no responsible gene for the observed linkage has so far been 
identified. 
Chromosome 11q has been linked to osteoarthritis in females at marker D11S901 in 
the UK cohort.46 This region has been narrowed into two distinct linkage intervals of 11.9 cM 
and of 6.5 cM.47 However, a recent study of 295 Russian nuclear families failed to find an 
association and linkage of 11q12-13 to hand osteoarthritis.45 Overall, it remains unclear 
whether the observed linkage in the UK cohort is a true finding. 
Several strong osteoarthritis genes have been mapped on chromosome 12. 
Chromosome 12q12-13.1 encompasses three closely located strong candidate genes i.e. the 
COL2A1 gene, the vitamin D receptor gene (VDR), and the insulin like growth factor 1 gene. 
The COL2A1 gene encodes α1 chain of type II collagen. This gene has been associated to 
osteoarthritis at multiple joints.65,84 These findings have been replicated within the Rotterdam 
CHAPTER 2.1                                                                                                                                                                                   . 
 
 
 
28 
study, where COL2A1 has been significantly associated to generalized,62 and knee 
osteoarthritis.58,85 However, others found no relation between this gene and osteoarthritis at 
hip or hand joints.56,86,87 The other potential chromosome 12 osteoarthritis susceptibility locus 
is the VDR gene. This gene has been associated to knee osteoarthritis in the UK cohort,88 and 
the Rotterdam Study.58,85 Several studies, on the other hand, failed to associate the VDR gene 
to osteoarthritis in knee, hip, or spinal joints in particular in women.86,89,90 The third 
chromosome 12 osteoarthritis susceptibility gene is the IGF-I gene that has been associated 
with radiographic osteoarthritis at multiple joint sites in the Rotterdam Study.59 Further 
analysis of osteoarthritis patients within the Rotterdam Study suggested an interaction 
between the COL2A1 and IGF-1 on susceptibility to radiographic osteoarthritis in persons 
aged less than 65 years.60 
Chromosome 16 shows two regions of weak linkage to osteoarthritis, the first on 16p 
and the second on 16q in the UK cohort.42 A significant association was found between the 
interleukin 4 receptor mapped on chromosome 16p12.3-12.1 and female hip osteoarthritis in 
the UK cohort.91 
There are several other chromosomal regions that have been linked or associated to 
osteoarthritis, but those linkages remain to be replicated. Chromosome 3p was linked to hand 
osteoarthritis at D3S1566.43 Within the Framingham Study, chromosome 15 and chromosome 
20 have been linked to osteoarthritis in the first carpometacarpal joint.34 There are other 
candidate genes, which have been described for osteoarthritis in small studies and are not 
mentioned in this review as they remain to be confirmed. 
Discussion 
We briefly reviewed the findings in genetic epidemiology of osteoarthritis. Hereafter few 
methodological points are further discussed.  
Model free or non-parametric linkage analysis looks for allele or chromosomal regions 
that are shared by affected individuals.92-94 Many osteoarthritis linked genomic regions clearly 
do not coincide and for many of them the gene has not yet been identified. The studies may 
differ in population structure,95 in underlying pathogenic pathways, in phenotype definitions 
i.e. radiographic and symptomatic osteoarthritis, in liability classes i.e. early onset versus late 
onset osteoarthritis, gender, pre-menopausal versus post-menopausal women with 
osteoarthritis, in osteoarthritis endo-phenotypes i.e. osteophytosis, nodal osteoarthritis, or 
cartilage loss, the extent of osteoarthritis i.e. generalized or a local form of osteoarthritis, 
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studied joints sites i.e. hand, hip, knee or spine, in interacting environmental factors, and in 
sample sizes.96-99 
Among the regions that have been linked or associated to osteoarthritis, regions on 
chromosome 6 are of special interest. There are several functional, experimental and knock-
out studies indicating a role for chromosome 6q COL9A1 gene in osteoarthritis. Nevertheless, 
to date, only the UK cohort found linkage to COL9A1 in affected sibling pairs with severe 
osteoarthritis. No other linkage studies have replicated this finding. The question still to be 
answered is whether COL9A1 is associated to osteoarthritis at hip as well as at other joint 
sites in population-based samples. Another chromosome 6p candidate gene for osteoarthritis 
is the HFE gene. Although, osteoarthritis is the main feature of hemochromatosis-associated 
arthropathy, little is known about the relation between the HFE mutations and osteoarthritis. 
Several studies associated the C282Y mutation to osteoarthritis and chondrocalcinosis, 
however, the generalizability of these studies has been questioned.100 Overall, the findings 
from experimental and linkage studies on the relationship between the COL9A1 gene and the 
strong association between hemochromatosis and arthropathy, warrants more detailed studies 
on the relationship between the COL9A1 and HFE genes and osteoarthritis. 
In summary, the term osteoarthritis refers to a group of etiologically and 
phenotypically heterogeneous disorders that mainly affects the joints. Twin studies and 
segregation analysis revealed a substantial heritability for osteoarthritis. Multiple genes may 
contribute to the development of osteoarthritis. From a pathologic perspective, the step 
forward is to identify these genes and determine how they function. From the public health 
perspective, the question is whether measuring a set of identified osteoarthritis genes can 
predict in future the susceptibility to osteoarthritis in an individual. Genetic studies aimed to 
identify new genes implicated in osteoarthritis may help to distinguish homogeneous groups 
of osteoarthritis or identify new pathways to underlying susceptibility to osteoarthritis. 
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Introduction 
Hemochromatosis includes several disorders of iron metabolism characterized by pathological 
accumulation of iron in tissues.1 Although there is no consensus on the definition of 
hemochromatosis, the disease is usually categorized into primary and secondary forms.2 
Primary hemochromatosis is referred to as hereditary hemochromatosis. It is an inherited 
disorder resulting from an inborn error of iron metabolism that leads to progressive iron 
loading of the parenchymal cells in the liver, pancreas, and heart.1 Secondary 
hemochromatosis referred to as acquired hemochromatosis, is an iron overload disorder that 
occurs as a result of chronic disorders of erythropoiesis such as thalassemia or sideroblastic 
anemia.2 
Hereditary hemochromatosis is one of the most common genetic disorders in 
populations of northern European descent with a prevalence of 0.2 to 0.5 percent.2-6 
Hemochromatosis can lead to multiple diseases like cirrhosis, hepatocellular carcinoma, 
cardiomyopathy, diabetes mellitus, amenorrhoea, impotence, arthritis, pituitary 
hypogonadism, and skin hyper pigmentation.1,7,8 Early symptoms and complaints include joint 
pain, abdominal pain, weakness and fatigue.8 Expression of the disease is modified by several 
factors, in particular dietary iron intake, blood loss associated with menstruation and 
pregnancy, and blood donation. The disease is 5 to 10 times more frequent in men than 
women and the age of onset is delayed in women.9 Hemochromatosis does not usually 
express before 20 years of age, although with genetic screening and periodic health 
examinations, asymptomatic subjects with iron overload can be identified in adulthood.  
For long, the diagnosis of hemochromatosis was based on the presence of excess iron 
in a liver biopsy in combination with serum iron, serum transferrin, and total iron binding 
capacity (TIBC).10,11 In 1996, Feder and colleagues reported that two mutations in the HFE 
gene, the C282Y and the H63D are associated with hereditary hemochromatosis. The C282Y 
mutation is found in about 85 percent of patients with hereditary hemochromatosis. Since 
then, diagnostic procedures have shifted to biochemical and genetic tests.12 Biochemical tests 
including serum iron, ferritin, and transferrin saturation level are now widely used in 
combination with genetic tests.13,14 Hemochromatosis has been regarded as a model disease 
for large-scale genetic screening.15,16 The aim of this chapter is to critically review the 
potential of genetic testing in hemochromatosis. Before we turn to preventive screening we 
will start with a brief review of the genetic epidemiology of hemochromatosis. 
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Genetic epidemiology of hemochromatosis 
In 1935, Sheldon suggested that hemochromatosis is an inborn error of iron metabolism.17 
Studies of familial aggregation have extended from the 1970's up to the 1990's. 
Hemochromatosis is indeed found more commonly in relatives of patients.18-23 Studies of the 
transmission of the disease in families suggest that hemochromatosis segregates usually as an 
autosomal recessive trait.24-26 Genetic and phenotypic heterogeneity are well-recognised 
features in hemochromatosis and it is becoming more and more evident that several genes or 
environmental factors may lead to the disease.17 Depending on the localisation of the genetic 
defect and the clinical phenotype, several types of hemochromatosis are distinguished. 
Type 1 hemochromatosis 
Type 1 hereditary hemochromatosis (HFE1 or simply HFE) is by far the most common form 
of hemochromatosis.1,2,13,27,28 The culprit gene, termed HFE, is located on human 
chromosome 6p21.3 and has two major mutations, c.845G→A (C282Y) and c.187C→G 
(H63D).12 Since its identification, over 37 other allelic variants of the HFE gene have been 
described.29 The localization of the HFE protein in the crypt cells of the duodenum, the site of 
dietary iron absorption and its association with the transferrin receptor in those cells are 
consistent with a role in regulating iron absorption.30-32 In HFE associated forms of 
hemochromatosis, the progression of iron overload is usually slow and affected individuals do 
not often present with clinical signs or symptoms until the fifth or sixth decade of life.33 Type 
1 hemochromatosis explains for a large part the prevalence of hemochromatosis (0.2 to 0.5 
percent) found in northern Europeans.3,5,28,33,34 HFE segregates in families as an autosomal 
recessive trait,23,25 and about 80 percent of clinically diagnosed probands of hemochromatosis 
patients are homozygous for the C282Y mutation in the HFE gene.1,12,35 
Type 2 hemochromatosis 
Type 2 hemochromatosis (HFE2), also called juvenile hemochromatosis, differs distinctly 
from type 1 hemochromatosis.36,37 This is a rare recessive form with a more severe disease 
phenotype that affects both sexes equally in the second decade of life.13 There is rapid iron 
loading and early onset of cardiac symptoms, endocrine dysfunction (hypogonadotrophic 
hypogonadism) and premature death.38,39 Kelly and colleagues (1998) reported a mean onset 
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of 22 years in patients from 3 pedigrees.40 It has been recently suggested that more than one 
gene may underlie the phenotype of juvenile hemochromatosis. 
Linkage to a locus on chromosome 1q has been found in patients with juvenile 
hemochromatosis. Recently, the putative gene encoding a protein designated hemojuvelin has 
been cloned that cause the main form of juvenile hemochromatosis.41 A deleterious G320V 
mutation in the hemojuvelin gene41 modulate hepcidin expression, a key protein implicated in 
iron metabolism.41-43 Others also confirmed that mutations in hemojuvelin cause juvenile 
hemochromatosis.44 A second rare form of juvenile hemochromatosis, with clinical 
expression identical to the 1q-linked form, is due to mutations in the HAMP gene leading to 
inactivation of hepcidin.45-47 Hepcidin is a hepatic antimicrobial-like peptide the deficiency of 
which leads to iron overload. 
Type 3 hemochromatosis 
Type 3 hemochromatosis (HFE3) is phenotypically similar to HFE1.13 The disease has been 
associated to the transferrin receptor 2 (TFR2) gene on human chromosome 7q22.48-50 The 
TFR2 gene is homologous to the transferrin receptor (TFRC) gene and is able to bind 
transferrin with lower affinity than TFRC. The TFR2 function is still unclear. TFR2 is spliced 
in two alternative forms, Alfa and Beta. The Alfa form is strongly expressed in the liver. The 
Beta form, coded from a start site in exon 4 of the Alpha has a low and ubiquitous 
expression.50 TFR2 mutations are very rare mutations. 
Type 4 hemochromatosis 
Contrary to the previously described forms of hemochromatosis, type 4 hemochromatosis or 
HFE4 segregates as an autosomal dominant trait.51-53 The clinical phenotype of patients in this 
case is quite similar to that of patients with HFE1 hemochromatosis but differs in that the 
disease is less severe and the pattern of iron loading is distinct.52-56 Iron accumulates 
predominantly in Kuppfer cells and other macrophages. Type 4 hemochromatosis (HFE4) is 
associated with various mutations (N144H, A77D, V162 del) in the SLC11A3 gene encoding 
the metal transporter called ferroportin (FPN1) alias, iron regulated transporter (IREG1) or 
metal transporter protein (MTP1) on human chromosome 2q.52-56 The exact mechanism by 
which mutations in the SLC11A3 gene causes autosomal dominant iron overload is still not 
known. Gain of function and loss of function of the protein have both been suggested,52,53 but 
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it is becoming more apparent that interactions between the SLC11A3 protein and other 
proteins involved in iron metabolism occur and can lead to iron accumulation.57 A form of 
autosomal dominant iron overload clinically distinct from type 4 hemochromatosis and which 
is due to a single point mutation (A49U) in the iron responsive element of the H ferritin 
mRNA has been reported in a single Japanese family.58 
Other types of hemochromatosis 
Other forms of hereditary iron overload include neonatal hemochromatosis, hyperferritinemia 
cataract syndrome, aceruloplasminemia, congenital atransferrinemia, and African iron 
overload. African iron overload is common in sub-Saharan Africa and is a distinct type of iron 
storage disorder.59 It is believed to result from increased dietary iron derived from traditional 
home-brewed beer. The etiology of neonatal hemochromatosis and hereditary 
hyperferritinemia cataract syndrome is not well understood. Aceruloplasminemia, and 
congenital atransferrinemia are due to the absence of ceruloplasmin and transferrin 
respectively and are secondary forms of iron overload. The pattern of iron deposition in 
patients suffering from these diseases is clearly different from that of classical 
hemochromatosis. Each of these disorders is rare. 
Occurrence of mutations involved in hemochromatosis 
HFE is the most widely studied gene that is involved in hemochromatosis. In the general 
Caucasian population, the carrier frequency of the C282Y mutation is estimated to be 10 
percent, and for the H63D mutation, 22 percent.28 In Caucasians, the most common form of 
hemochromatosis is due to homozygosity for the C282Y mutation or compound 
heterozygosity for the C282Y and H63D mutations in the HFE gene.12 The proportion of 
hemochromatosis due to HFE mutations varies in different parts of the world. Figure 1 
summarizes the published frequencies of carriers of HFE mutations in different populations 
(adapted from Hanson and colleagues 2001).34 Most C282Y and H63D carriers are found in 
the United States of America and Europe. About 65 percent of the population of these two 
continents are homozygous for the wild type or normal allele compared to 85 percent in India, 
and about 95 percent in Africa, the Middle East, and Asia. 
Up until now all other mutations involved in hemochromatosis are found to be rare, 
the contribution of HFE2 gene to the occurrence of hemochromatosis is thought to be limited
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Figure 1. Frequencies of HFE C282Y and H63D mutations in different populations. 
to a few families.40,60 TFR2 mutations are rare but may occur frequently in the Italian 
population.61 Although several mutations have been reported for the SCL11A3 gene, these 
mutations are thought to be rare in the general population. 
Is genetic testing worthwhile? 
In recent years there has been increasing interest in screening populations for 
hemochromatosis.5,32,62,63 Hemochromatosis is an excellent example of a disease that meets 
the World Health Organization recommendations and the US preventive services task force 
criteria for a screening program. The disorder is common, it has a prolonged asymptomatic 
and early symptomatic phase, and if untreated can result in serious morbidity and premature 
death. Simple and effective screening tests for iron overload are available and there is a 
reliable confirmatory test. The treatment is safe and acceptable and in some countries the 
blood collected from venesection treatment is utilized by the blood transfusion services. It is 
still a matter of debate whether we should screen for hemochromatosis and if yes whether the 
test should be based on biochemical levels of serum iron parameters or based on the presence 
of common mutations in the HFE gene.15,63-66 On the other hand, screening using DNA 
analysis is simple to carry out and has the additional advantage of detecting subjects with 
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delayed or incomplete penetrance, allowing diagnosis at an early age and treatment to prevent 
clinically significant iron overload.67 However, not all subjects with iron overload carry the 
C282Y mutation.27 This mutation is mainly found in Caucasians. This limits the application 
of this screen test to other ethnic groups. On the other hand, phenotypic measures such as 
biochemical iron levels are early indicators of disease but they have a low specificity and are 
less valuable for screening strategy. Phenotypic expression of hemochromatosis is very much 
influenced by age, diet, blood loss and menstruation, pregnancy and gene-gene interaction. 
Another important parameter in evaluating a screening program is the cost- 
effectiveness of the latter. This is assessed by comparing the total diagnostic costs to the extra 
costs arising from managing the disease. Studies have shown that population screening for 
hemochromatosis is cost effective.68,69 However screening for hemochromatosis like many 
other diseases has several disadvantages, among others ethical concerns, psychological 
troubles, over-medicalisation, and if screening is based on the genotype, many subjects with 
iron overload due to other reasons will be missed. Little is known of the psychological impact 
and ethical implications of a screening program for hemochromatosis. There is still lack of 
information on the natural history of the disease and the age-related penetrance of the disease 
is still unknown. 
In deciding whether or not to screen, important quantitative parameters that should 
help in the decision are the positive predictive value (PPV), the sensitivity and the specificity 
of the test used. The PPV, the probability that a person with a positive test result will develop 
the disease is approximately equal to the penetrance of the disease and is a function of the 
frequency of the susceptibility-conferring genotype, the relative risk of the disease and the 
risk of disease in a given population.70 It can be calculated as follows: PPV=[R (D) *100] / [G 
(R-1) +1], where R is the relative risk, D the incidence of the disease and G the frequency of 
the susceptibility conferring genotype.71 Our study in the elderly population has shown that 
for all HFE mutations, the PPV was 10 percent in men and 5 percent in women.  
The sensitivity (the probability that the test correctly classifies people with preclinical 
disease as positive) was 70 percent for men and 52 percent for women and the specificity (the 
probability that the test classifies as negative those who will not have the disease) was 62 
percent for men and 64 percent for women.72 A more or less important quantitative parameter 
is the population attributable risk (PAR). This is the proportion of cases of a disease that can 
be attributed to the susceptibility-conferring genotype. It can be calculated as follows; PAR= 
[G (R-1) *100]/(G (R-1) +1, where G is the frequency of a susceptibility conferring genotype 
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and R is the relative risk.71 Only in the case of polymorphisms that have frequencies in the 
range of 10 to 30 percent and that increase susceptibility to disease will the PAR be 
appreciable. Single, highly penetrant gene mutations cause only a small proportion of the 
disease.73 Our results in a population-based setting suggest that many sub-clinical cases of 
hemochromatosis will be missed when screening is based on HFE genotypes. These findings 
in the general elderly population suggest that the value of screening for high iron based on 
HFE genotypes is limited in that only a small percentage of subjects with elevated levels of 
iron will be detected. However, the aim of a population-based screening is to identify at an 
early stage individuals at risk of developing serious iron overload, to prevent organ damage. 
Although not all patients may be found, the implications for those who are found are high 
despite the controversy of the role of HFE in disease. 
One reason why genetic screening for complex diseases is not advocated is that the 
risk for disease does not only depend on the gene but also on other factors like the 
environment, nutrition and genetic modifiers. Penetrance depends on at least six factors: (1) 
the importance of the function of the protein encoded by the gene, (2) the functional 
importance of the mutation, (3) the interaction with the environment, (4) onset of somatic 
mutations, (5) interaction with other genes, and (6) existence of alternative pathways that can 
substitute for the loss of function. 
Another point of concern is the definition of the phenotype. There is no consensus on 
the definition of hemochromatosis and also no agreement on the clinical features of the 
disease among clinicians and experts. This situation has led to several approaches in 
estimating the penetrance of HFE mutations. While some authors consider clinical 
hemochromatosis as the end point, others have used combinations of signs and symptoms of 
hemochromatosis as end point to estimate the penetrance while other investigators have used 
phenotypic measures such as serum iron indices. These diverging outcomes have obviously 
led to diversity in quantification and estimates of penetrance. Four stages of the disorder are 
generally recognized; the genetic predisposition but without any abnormality, iron overload 
without any symptom, iron overload with early symptoms (lethargy, arthralgia), and iron 
overload with organ damage (cirrhosis especially).1 Some authors74 have argued that the 
excess of iron may not translate to associated diseases of hereditary hemochromatosis such as 
diabetes, but other disorders such as atherosclerosis, cancer. This hypothesis is supported by 
our own data suggesting that HFE is involved in artherosclerosis, particularly in smokers.75 
We have studied the association between the HFE mutations, carotid artherosclerosis, and 
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stroke. We observed that in the presence of additional risk factors (smoking and 
hypertension), there is increased risk of carotid artherosclerosis and stroke in carriers of HFE 
mutations.75 HFE mutations only showed an overall weak association with stroke (odds ratio 
(OR) 1.3; 95% confidence interval (CI), 0.8 to 2.2). But patients with hypertension who were 
also carriers of the HFE mutations showed a significantly increased risk of stroke (OR 3.0; 
95% CI, 1.9 to 4.6). Also HFE carriers who were also smokers had an increased risk of stroke 
(OR 2.6; 95% CI, 1.4 to 5.0). We conclude that HFE mutations modify the risk of stroke in 
subjects who already carry traditional risk factors.  
Concerning the relationship with diabetes, we conducted a meta-analysis of the 
association between HFE mutations and diabetes and did not find any indication of an 
increased risk of diabetes in carriers of the HFE mutations (Figures 2 and 3).76 Also in a 
population-based sample of elderly, we observed that 11 percent of patients with type 2 
diabetes and 10.6 percent of controls were carriers of the C282Y mutation (OR 1.0, 95% CI, 
0.6 to 1.7). For the H63D mutation, 25.7 percent of type 2 diabetes patients and 28.5 percent 
of control subjects were carriers (OR 0.8, 95% CI, 0.6 to 1.1).70 Are the studies biased 
towards the null due to survival bias? This is difficult to believe but not impossible. 
 
 
Figure 2. Meta-analysis of the frequency of the C282Y mutation in patients with type 2 diabetes. 
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Figure 3. Meta-analysis of the frequency of the H63D mutation in patients with type 2 diabetes. 
Conclusion 
Hemochromatosis is a common genetic disease in Western populations. The potential for 
genetic screening for mutation carriers is a priori high. Although findings have been negative 
in the largest study to date, the possible biases in this study, addressed elsewhere,77 leave the 
question to be answered whether screening for the HFE mutations is worthwhile. Our findings 
in the general elderly population suggest that the value for high iron based on HFE genotypes 
is limited, and only a small percentage of subjects with elevated levels of iron will be 
detected. However, the aim of a population-based screening is to identify at an early stage 
individuals at risk of developing serious iron overload so that treatment can be started to 
prevent organ damage. Not all patients may be found; the implications for those who are 
found are high. Thus, screening is helpful to identify high-risk groups. 
In assessing the feasibility of screening for hemochromatosis, attention should not be 
directed only to the disease genotype or phenotype but also to the human being as end 
beneficiary. The translation of genetic and epidemiological advances in the field of 
hemochromatosis calls for studies on the cost-effectiveness, cost-benefit and cost-utility of 
screening for hemochromatosis to be carried out. From this point of view, all information 
critical for the assessment and implementation of population screening for hemochromatosis 
are still lacking and need the input and cooperation of scientists in several fields of research. 
Although many consider hemochromatosis as a good example of a disease that meet the 
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criteria for genetic screening, some key information is still necessary before genetic screening 
can be assessed. 
The differential risk of disease seen with different genotypes and the evidence of 
incomplete penetrance for the genotype conferring the highest risk make genetic screening for 
hemochromatosis less worthy. 
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Abstract 
Collagen IX proteoglycan is an important protein in collagen networks and has been 
implicated in hip osteoarthritis. We studied two COL9A1 markers (509-8B2 and 509-12B1) 
in relation to radiographic osteoarthritis in the Rotterdam Study, a population-based study of 
7983 subjects aged 55 years or over. We used two different designs. First a sibling-pairs study 
of 83 probands with radiographic osteoarthritis at multiple joints, and their 221 siblings 
yielding 445 sibling pairs who participated in the study. Second, an association study in a 
series of 71 patients with hip radiographic osteoarthritis and 269 controls. All subjects were 
characterized for the two COL9A1 509-8B2 and 509-12B1 markers. The mean test was used 
to assess the proportion of alleles shared in concordantly affected and unaffected sibling pairs. 
The chi-squared test was used to compare the allele distributions in cases and controls. We 
found that affected sibling-pairs with radiographic osteoarthritis at hip joints shared 
significantly (p<0.05) more often alleles identical by descent (IBD) at the 8B2 (mean 0.66± 
standard error 0.07) and 12B1 (0.65±0.08) markers than expected. No excess sharing was 
observed for radiographic osteoarthritis at other joint sites. When comparing the allele 
frequency of 8B2 and 12B1 in cases and controls, the frequency of 8B2 alleles in cases 
differed significantly (p<0.01) from that of controls. Our data suggest that susceptibility for 
hip osteoarthritis is conferred within or close to the COL9A1 gene in linkage disequilibrium 
with the COL9A1 509-8B2 marker. 
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Osteoarthritis is a common complex disorder worldwide1 and is the leading cause of disability 
and pain in the elderly.2 Family-based and candidate gene studies demonstrated a clear 
genetic component for primary osteoarthritis.3,4 One of the main pathological characteristics 
of osteoarthritis is the degradation of hyaline cartilage. The collagen fibril networks is one of 
the essential components that maintains the integrity of hyaline cartilage and prevents its 
degradation.5 Among collagen fibrils, type IX collagen links the collagen type II-containing 
fibrils to the rest of the cartilage matrix, and thus plays a role in the cartilage integrity.6 Type 
IX collagen is composed of three genetically distinct alpha (α) polypeptide chains i.e. α1(IX), 
α2(IX), and α3(IX), encoded by COL9A1, COL9A2, and COL9A3, respectively.6 
Deficiency of α1(IX) polypeptide has been shown to lead to functional abnormality in 
collagen IX fibrils, and thus to instability of hyaline cartilage.7 This observation suggests that 
mutations in the COL9A1 gene that leads to a non-functional α1(IX) polypeptide may be 
implicated in osteoarthritis. There are some evidences to support this view. Transgenic mice 
that express a non-functional protein as well as knock-out mice indeed develop osteoarthritis8 
suggesting COL9A1 as a candidate gene for osteoarthritis in human. There is some evidence 
that this gene is involved in hip osteoarthritis.9,10 Affected sibling-pairs studies found linkage 
of COL9A1 to a severe form of hip osteoarthritis in women.9,10 However, association studies 
failed to show any relationship.9 Another question that remains to be answered is whether 
COL9A1 is involved in other joints than the hip. 
In the present study, we investigated two polymorphisms in the COL9A1 gene (509-
8B2 and 12B1) in relation to radiographic osteoarthritis at different joint sites in two 
independent studies, a sibling-pairs study including 445 pairs with hip, knee, and hand 
radiographic osteoarthritis or spinal disk degeneration, and an association study of 71 persons 
with radiographic osteoarthritis at hip joints and 269 controls.  
Methods 
Study population The present study was conducted in the framework of the Rotterdam 
Study, a population-based cohort study of chronic diseases in 7983 subjects aged 55 years or 
over.11 The medical ethics committee of the Erasmus Medical Center has approved the study. 
Written informed consent was obtained from all participants. Baseline examination took place 
between 1990 and 1993 by means of a structured interview using standardized questionnaires.
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Figure 1. Flow-chart outlining the participation of probands, and siblings in the linkage study 
and cases and controls in the association study. 
Figure 1 presents a flow-chart of the participation of the study population. From the total 
cohort of subjects aged 55 to 65 years (n=2593), a random cohort including 944 non-
institutionalized persons was drawn and scored for radiographic osteoarthritis at hip, knee, 
and hand joints and for disk degeneration of the spine. 
Radiographic examination Radiographs of hip, knee, and hand joints of participants of the 
Rotterdam Study, and the siblings were scored for the presence of radiographic osteoarthritis. 
Radiographs of the spine were evaluated for the presence of disk degeneration as proposed by 
Kellgren and Lawrence.12 The diagnosis of radiographic osteoarthritis was considered for any 
joint with a Kellgren score two or higher. Two independent readers scored all radiographs. 
After each set of about 150 radiographs, the scores of the two readers were evaluated. 
Whenever the scores were two or more points different, or was two for one reader but one for 
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the other, a consensus was agreed upon. All radiographs were scored before genotyping and 
this was performed blind to clinical data. 
Linkage study- For linkage analysis, probands were derived from the random cohort. 
Persons who had radiographic osteoarthritis at two or more joint sites of the four joint groups 
i.e. hips, knees, hands, or the spine were selected as probands. In case individuals had hand 
radiographic osteoarthritis and disk degeneration of the spine, which was the most common 
combination observed, additionally they had to have Heberden’s nodes to be included as 
probands. This criterion was applied to maximize the probability of a genetic form of 
radiographic osteoarthritis. Two hundred and twenty-one (response rate 88 percent) probands 
were willing to contribute to the study, yielding 708 siblings born alive (Figure 1). Four 
hundred and fifty siblings of 101 probands were not eligible for the study due to siblings 
death, refusal, emigration, disease, and non-response. In total, 258 siblings and 120 probands 
derived from 120 pedigrees were included in the study. The siblings were examined at the 
research center using the same protocol and methods as those used to examine the participants 
in the random cohort. 
Association study- Within the random cohort, 72 persons with radiographic 
osteoarthritis at hip joints were genotyped. The 269 persons who did not have radiographic 
osteoarthritis at hip, knee, or hand joints were selected as controls (Figure 1). 
Genotyping for COL9A1 509-8B2 and 12B1 markers Participants were genotyped for 
COL9A1 509-8B2 and 12B1 short tandem repeat polymorphism (STRP) according to the 
protocol of Warman and colleagues.13 Genotyping was successful for 85 probands and 241 
siblings in the sibling pair study, and in the association study, for 71 cases, and all controls 
except for 8B2 in 1 control subject (Figure 1). 
Data analysis 
Linkage study- Familial relation between siblings was confirmed using the genealogical data. 
There were six half sibs who were excluded from the analysis (Figure 1). Mendelian 
inconsistency in pedigrees was checked using MARKERINFO module. Given the siblings 
genotypes in nuclear families, this module reconstructs siblings’ genotypic sets and thereafter 
the parental genotypes. Pedigrees with Mendelian inconsistency are identified whenever one 
or two alleles of the studied markers in any sibling do not match with the family genotypic 
sets. Two probands and 14 full siblings, who belonged to 4 pedigrees with Mendelian 
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inconsistencies in 1 or both of the two markers, were excluded from the analysis (Figure 1). 
The remaining 83 probands and 221 siblings of 100 pedigrees yielded a total number of 445 
sibling-pairs. Sibling pairs were classified according to affection status as concordantly 
affected i.e. both siblings had radiographic osteoarthritis, concordantly unaffected i.e. both 
siblings had no radiographic osteoarthritis and discordant siblings i.e. one sib was affected 
with another sib unaffected at the studied joint site. We used the mean test, which is a 
powerful test for additive inheritance to compare the average proportion of allele shared IBD 
with the expected value of 0.5.14 On average, sibling pairs share half of the alleles at a given 
locus IBD. Concordantly affected sibling-pairs should share alleles IBD more than 50 percent 
at COL9A1 if this locus is linked to radiographic osteoarthritis. The analysis was adjusted for 
age and gender, the two major determinants of osteoarthritis. Sibling-pairs data was analyzed 
using S.A.G.E. version 4.4. 
Association study- Allele and genotype frequencies for the 8B2 and 12B1 markers 
were estimated by counting alleles and estimating sample proportion. Allele and genotype 
proportions were tested for Hardy Weinberg equilibrium. The chi-squared test was used to 
compare allele frequencies between cases and controls.   
Results 
Table 1 shows the characteristics of the study population. The mean age of siblings was 
significantly (p<0.001) higher and body mass index was lower (p<0.05) than that of probands. 
In the final analysis each pedigree contributed on average 4.5 (range 1 to 36) sibling pairs to 
the linkage study. Among probands, 33 percent had radiographic osteoarthritis at hip, 78 
percent at knee, 78 percent at hand joints, and 64 percent had spinal disk degeneration. 
Among the siblings, 7 percent had radiographic osteoarthritis at hip, 19 percent at knee, 75 
percent at hand joints, and 79 percent had spinal disk degeneration. In the association study, 
there was no significant difference in gender, body mass index, or bone mineral density 
between cases with hip radiographic osteoarthritis and controls. Cases were slightly (1 year) 
older than controls (p=0.05). Allele and genotype proportions were in Hardy Weinberg 
equilibrium.  
Table 2 shows the results of the linkage analysis in affected and unaffected sibling 
pairs. Affected sibling pairs (n=11) with radiographic osteoarthritis at hip joints had a 
significant (p<0.05) excess in IBD allele sharing in the COL9A1 8B2 (mean 0.66± standard  
error 0.07) and 12B1 (0.65±0.08) markers. 
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Table 1. Characteristics of the study population.† 
 Linkage study Association study 
 Probands Siblings  Cases  Controls 
Number 83  221  71  269 
Age (years) 60.90±2.71*  65.80±8.
02 
 60.76±2.43**  59.71±2.84 
Women (%) 69.22  50.25  41.66  49.07 
Body mass index 
(kg/m2) 
27.36±4.23  26.71±4.
01 
 26.45±3.46  25.65±3.26 
Bone mineral 
density (cg/cm2) 
0.91±4.23*  0.86±0.1
4 
 0.90±0.13  0.87±0.13 
Frequency of families by the number of sibling pairs  
  
 Number of 
families 
 Number of 
contributing 
sibling-pairs 
    
 1 sibling-pair 54  54     
 3 sibling-pairs 20  60     
 6 sibling-pairs 12  72     
 10 sibling-pairs 4  40     
 11 sibling-pairs 1  11     
 15 sibling-pairs 3  45     
 21 sibling-pairs 3  63     
 28 sibling pairs 1  28     
 36 sibling-pairs 2  72     
†Mean± standard deviations are presented. *p<0.05 compared to siblings; **p<0.05 compared to 
controls. 
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Table 2. Mean proportion (± standard errors) of COL9A1 509-8B2 and 12B1 alleles shared identical 
by descent (IBD) over the presence of radiographic osteoarthritis. 
COL9A1 
marker  
Sibling-pairs 
phenotype† 
 Joint site with radiographic osteoarthritis 
 Hip Knee Hand  Spine 
 
 n  n  n   n  
509-8B2 Concordantly 
affected 
 11 0.66±0.07* 41 0.49±0.05 251 0.51±0.02  243 0.52±0.02
 
Concordantly 
unaffected 
 327 0.50±0.02 205 0.51±0.02 26 0.52±0.06  39 0.54±0.06
            
509-12B1 Concordantly 
affected 
 11 0.65±0.08* 30 0.50±0.05 251 0.50±0.02  243 0.50±0.02
  
Concordantly 
unaffected 
 327 0.49±0.02 212 0.49±0.02 26 0.52±0.07  39 0.50±0.06
*p<0.05 indicating a significant increase in mean proportion of alleles shared IBD from the 
expected value of 0.5. †The data on discordant pairs was not presented. 
The 11 sibling pairs with hip radiographic osteoarthritis belonged to 9 families consisted of a 
total number of 19 siblings (1 family contributed 3 affected sibling-pairs). Among the sibling 
pairs with radiographic osteoarthritis at hip joints, 3 pairs were homozygous for COL9A1 8B2 
allele 5/ allele 6 genotype i.e. both siblings had the 5/6 genotype, 2 pairs for 5/5 and 1 pair for 
4/6. The remaining sibling-pairs were heterozygous for 8B2 i.e. two sibling-pairs had a 5/5 
and 5/6 genotype set, one 5/2 and 5/6, one 5/4 and 9/4, one 5/6 and 9/6. When considering the 
12B1 marker, 2 sibling-pairs were homozygous for 4/6 genotype, 1 pair for 4/8 and 1 pair for 
4/4 genotype. The rest of sibling-pairs were heterozygous for 12B1 i.e. two pairs had 4/4 and 
4/8 genotype sets, 2 pairs had 4/6 and 5/6, 1 pair had 4/8 and 8/8, 1 pair had 4/4 and 4/6, and 1 
pair had 3/6 and 3/5 genotype set. No significant differences for the other joints were 
observed. The number of allele shared in affected and unaffected sibling-pairs were similar 
suggesting there is no evidence for a role of COL9A1 in radiographic osteoarthritis at other 
joints. The frequency of 8B2 or 12B1 alleles was not significantly different between negative 
controls and the total population. Table 3 shows the frequency of 8B2 and 12B1 alleles by the  
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Table 3. Frequency of COL9A1 509-8B2 and 12B1 alleles by radiographic osteoarthritis (ROA) at hip
joints. 
COL9A1 
marker 
Hip ROA Alleles 
P 
value
  5 6 7 8 9 Others*   
509-8B2 Present 50 (0.35) 27 (0.19) 14 (0.10) 10 (0.07) 20 (0.14) 21 (0.15)  0.01
 Absent 231 (0.43) 140 (0.26) 29 (0.05) 22 (0.04) 62 (0.12) 52 (0.10)   
          
  2 4 5 6 7 8 Others*  
509-12B1 Present 14 (0.10) 50 (0.35) 27 (0.19) 15 (0.11) 5 (0.03) 23 (0.16) 8 (0.06) 0.10
 Absent 96 (0.18) 172 (0.32) 67 (0.12) 44 (0.08) 33 (0.06) 92 (0.17) 34 (0.06)  
Figures are numbers (frequencies). *Alleles with a frequency of less than 0.05 are summed in the category 
others. 
presence of radiographic osteoarthritis at hip joints. The frequency of 8B2 alleles differed 
significantly (p≤0.01) between subjects with compared to those without radiographic 
osteoarthritis at hip joints. The frequency of 12B1 alleles was not significantly different 
between subjects with and without radiographic osteoarthritis at hip joints. 
Discussion 
In this population-based study, we found that affected sibling pairs with radiographic 
osteoarthritis at hip joints shared significantly higher number of alleles IBD at 2 markers in 
COL9A1 (8B2 and 12B1 STRPs). Further, in the association study, we found that 8B2 marker 
was significantly associated to radiographic osteoarthritis at hip joints. 
The positive linkage of the COL9A1 locus in our sibling-pairs confirmed earlier 
findings of linkage in female sibling-pairs with hip osteoarthritis,9,10 although we could not 
stratify for gender as the numbers were too low for a meaningful statistical analysis. Despite 
the fact that the number of sibling-pairs was small in our study, the excess of sharing was 
statistically significant. Also in our association study, we found a significant relation between 
the COL9A1 8B2 marker and radiographic osteoarthritis at hip joints. The relevance of our 
finding is not completely clear since the significance was marginal, various alleles together 
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contribute to the association and no association was found to the nearby 12B1 marker. One 
previous association study on the relation between COL9A1 8B2 and 12B1 markers and 
radiographic osteoarthritis has been reported. No association of 8B2 or 12B1 with severe hip 
osteoarthritis was found in a study of 146 women selected from families with osteoarthritis.9 
There are two important points of consideration when interpreting the difference 
between our findings and those of Loughlin and colleagues (2000).9 First, in contrast to a 
linkage study the relation in an association study can be easily missed since the marker used 
in the two studies is not very powerful for association analysis due to a large number of rare 
alleles. The genetic information content of a marker depends on heterozygosity index, a 
function of marker allele frequencies, as well as on the location of the marker on genome 
map, and the functional effect of the marker variants. In the present study, the polymorphic 
nature of the studied markers resulted in multiple strata of cases and controls thus 
demolishing the power of the association study. Second, although we hypothesize that the 
COL9A1 locus contributes to osteoarthritis susceptibility, the 8B2 marker is not likely 
causally related to radiographic osteoarthritis. 8B2 is located in COL9A1 intron 4 that resides in 
17.7 kilobase (kb) downstream of the start of a haplotype block of 65 kb within COL9A1. 
This haplotype block is encompassed by intron 1 (-501) to intron 34 (+32).9 Thus 8B2 may be 
in strong linkage disequilibrium with other COL9A1 mutations. 12B1 is located 14.3 kb 
upstream of exon 1 and resides outside the COL9A1 haplotype block. Further, COL9A1 
mapped to a region where other FACIT-like collagen e.g. COL19A115 have been also 
mapped. Although the association of marker 8B2 with hip osteoarthritis might be explained 
by linkage disequilibrium with adjacent loci which suggests an osteoarthritis susceptibility 
locus may map near to COL9A1 locus, several experimental studies support the role of 
COL9A1 locus in osteoarthritis.7,8 Those studies7,8 showed that COL9A1 gene knockout mice 
developed early-onset osteoarthritis.  
Taken together with earlier findings, our data suggest that osteoarthritis susceptibility 
may map within or near to the COL9A1 gene, with 509-8B2 simply being a marker for this. 
In our sibling-pairs data, there was no evidence for a role of COL9A1 in other forms of 
osteoarthritis. Further studies are necessary to identify the underlying mutation in COL9A1 or 
within a nearby osteoarthritis susceptibility locus. 
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Abstract 
Arthropathy is one of the most common manifestations in patients with hereditary 
hemochromatosis. The HFE C282Y and H63D mutations are the most common causes of 
hereditary hemochromatosis. We investigated the relation between the HFE C282Y and 
H63D mutations with arthralgia and joint pathology in the population-based Rotterdam Study. 
From a cohort of 7983 people aged 55 years or over, 2095 randomly drawn subjects were 
genotyped for C282Y and H63D mutations. We compared the frequency of arthralgia, and the 
presence of chondrocalcinosis, osteophytes, joint space narrowing and osteoarthritis at 
radiographs of hand, hip and knee joints, and Heberden’s nodes in carriers of HFE mutations 
to that in non-carriers. Overall, there was a significantly higher frequency of arthralgia (odds 
ratio 1.6; 95 percent confidence interval 1.0 to 2.6), oligoarthralgia (2.3; 1.2 to 4.4) and 
Heberden’s nodes (2.0; 1.1 to 3.8) in those homozygous for H63D compared to non-carriers. 
In persons aged 65 years or younger, H63D homozygotes had significantly more often 
polyarthralgia (3.1; 1.3 to 7.4), chondrocalcinosis at hip or knee joints (4.7; 1.2 to 18.5), 
increased number of hand joints with osteophytes (mean 6.1± standard deviation 1.0 versus 
4.4±0.3), joint space narrowing (2.8±0.5 versus 1.0±0.1), radiographic osteoarthritis (4.4±0.7 
versus 2.0±0.2), and Heberden’s nodes (3.1; 1.3 to 12.8). We found no relation of arthralgia 
or joint pathology to C282Y, but compound heterozygotes had a significantly higher 
frequency of arthralgia (2.9; 1.0 to 9.3), chondrocalcinosis at hip (6.5; 1.8 to 22.3), and 
increased number of osteophytes at knee (6.9±1.2 versus 2.4±0.1) joints at late age (65 years 
or over). The HFE H63D mutation may explain at least in part the prevalence of arthralgia at 
multiple joints sites, chondrocalcinosis, and hand osteoarthritis in the general population. 
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In type I hereditary hemochromatosis, arthralgia affects up to 85 percent of patients,1-6 
seriously influencing quality of life.7 Hand and knee are the joints most often affected.8-10 
Most of our knowledge on the relationship between hemochromatosis and arthropathy is 
developed studying patients or families with the hereditary form of the disease. In patients 
with hemochromatosis, arthropathy may originate from a progressive degenerative arthritis 
initially presenting at hand joints,9, 10 but can also originate from an inflammatory mediated 
condition like chondrocalcinosis.9, 10, 12 Occasionally, arthropathy in hemochromatosis may 
resemble rheumatoid arthritis,8, 9 accompanied by Heberden’s nodes.13 Main radiographic 
findings in hemochromatosis arthropathy are calcium crystal depositions, osteophytes and 
joint space narrowing.9, 10 
The C282Y and H63D mutations in the HFE gene are the most common mutations 
involved in hereditary hemochromatosis.5, 14-16 Eleven percent of Caucasians are carriers of 
C282Y and 23 percent of the total population worldwide are carriers of H63D.15 The risk of 
hemochromatosis is increased for those homozygous for C282Y (4383 folds) or compound 
heterozygotes i.e. carriers of both H63D and C282Y (32 folds).15 Also, H63D homozygotes 
are estimated to have a 6 fold increased risk of hemochromatosis,15  although iron levels are 
modestly increased.15, 17, 18 
Findings on the relation between HFE mutations and arthropathy are neither consistent 
nor conclusive. Some studies found no relation between C282Y and self-reported 
arthropathy,19 inflamed joints,20 chondrocalcinosis,21, 22 or subchondral arthritis.21 Other 
studies reported a significant association between C282Y and chondrocalcinosis,23 or late 
onset hand osteoarthritis.22 Few studies addressed the role of H63D.21, 22 The generalisability 
of these studies has been a matter of concern.24 We have studied the HFE C282Y and H63D 
mutations in the population-based Rotterdam Study.18, 25 The mutations were studied in 
relation to arthralgia as well as joint pathology assessed at radiographs including 
chondrocalcinosis at hip or knee joints, presence of osteophytes, joint space narrowing, 
radiographic osteoarthritis at hand, hip or knee joints, and Heberden’s nodes. Further, we 
investigated the relation between HFE, joint pain and overall mortality. 
Methods 
Population This study was carried out in the framework of the Rotterdam Study, a 
population-based cohort study of major chronic diseases. The medical ethics committee of 
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Erasmus Medical Center has approved the study and informed consent was obtained from all 
participants. The design and objectives of the study have been described elsewhere.26 In brief, 
the study population consists of 7983 inhabitants aged 55 years or over living in the district of 
Ommoord in Rotterdam. Baseline examinations took place between 1990 and 1993 by means 
of a structured interview using a standardized questionnaire. From the total cohort, 2095 
subjects randomly drawn were genotyped for the HFE C282Y and H63D mutations. In the 
Rotterdam Study, participants were followed up to 11.3 years. During the follow up period, 
information on the vital status of all participants was obtained at regular intervals from 
municipal health authorities in Rotterdam. The data on hospital admissions and a 
corresponding diagnosis of hemochromatosis were retrieved from interviewing participants, 
and medical records of the participants’ general practitioners. 
Main outcome measures At baseline examination, participants were asked whether they had 
any pain or other complaints in or around their joints. If yes, the research physicians 
questioned participants about the site and duration of joint complaints. The study physicians 
asked participants whether they had a medical diagnosis of orthopedic, traumatic, 
rheumatologic, or other diseases and whether they used any kind of pain medication or were 
treated with physiotherapy because of their joint complaints. Further at the research center, 
study physicians examined the hand of participants for the presence of Heberden’s nodes, a 
common local form of osteoarthritis at distal interphalangeal joint with inflammatory episodes 
associated with generalized osteoarthritis.29, 30 Within the randomly selected cohort (n=2095), 
clinical data were available on the presence of arthralgia for 2047 and on the presence of 
Heberden’s nodes for 1833 of subjects. 
The baseline anteroposterior radiographs of hip and knee joints of a random subset of 
the population were scored for the presence of chondrocalcinosis by two independent 
observers who were blinded to all information on participants as explained elsewhere.27 
Presence of osteophytes and space narrowing in anteroposterior radiographs of hands were 
assessed in the distal and proximal interphalangeal joints, the interphalangeal joint of thumb, 
the metacarpophalangeal joints, the first carpometacarpal joints, and the trapezoscaphoideal 
joints. Radiographic osteoarthritis at hand, hip and knee joints were graded as proposed by 
Kellgren and Lawrence.28 The diagnosis of radiographic osteoarthritis was considered for any 
joint with a Kellgren score two or higher. Within the randomly selected cohort, the data on 
presence of chondrocalcinosis at hip or knee joints were available for 1132 persons, on the 
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presence of osteophytes, joint space narrowing and radiographic osteoarthritis at hand joints 
for 1274, at knee joints for 1112 and at hip joints for 1352 persons. Finally, for H63D or 
C282Y homozygotes (n=65), all radiographs at baseline and follow up were re-examined for 
the presence of osteophyte, joint space narrowing, sclerosis, cyst formation, calcification, and 
chondrocalcinosis in subchondral bone at hand, hip and knee joints and at spinal joints for 
disk degeneration, spondylophytes, and calcification by a rheumatologist who was blinded to 
clinical data. 
Blood samples were collected on the day of baseline examination by venepuncture. 
Mutations analysis was performed as described elsewhere.14 
Data analysis The extent of arthralgia was classified into 4 groups. The first group consisted 
of those without arthralgia (the reference group), the second group of those with pain at one 
joint site, the third group of those with pain at two joint sites (oligoarthralgia), and the fourth 
group of those with pain at three or more joint sites (polyarthralgia). Presence of osteophytes 
at hand joints was transformed to a quantitative trait by summing up the number of joints with 
osteophytes. The same procedure was applied for the presence of joint space narrowing and 
radiographic osteoarthritis. The HFE C282Y genotypes were modeled by assigning a value of 
0, 1 or 2 for carriers of no (non-carriers), one (C282Y heterozygotes), or two (C282Y 
homozygotes) copies of the C282Y mutation, respectively. The same procedure was carried 
out for H63D. Genotype proportions were tested for Hardy Weinberg equilibrium. 
Independent t statistics, ANOVA and χ2 tests were used for comparisons of means and 
frequencies. We fitted statistical models using logistic regression analysis to test the 
association of C282Y or H63D and the risk of arthralgia overall and at different joint sites, 
chondrocalcinosis at hip or knee joints, or Heberden’s nodes in the right and/or left hand, and 
radiographic osteoarthritis at hip or knee joints. The magnitude of the association was 
expressed as odds ratio (OR) with 95 percent confidence interval (95% CI). Univariate 
regression analysis was used to estimate mean with the standard errors for the number of hand 
joints with osteophytes, joint space narrowing, or radiographic osteoarthritis by the HFE 
genotypes. For the study of mortality, we used Cox proportional regression analysis. All 
analyses were adjusted for age and gender. As a relation of C282Y heterozygosity to hand 
osteoarthritis was found in patients aged 65 years or over,22 and since differences may exist in 
the etiopathogenesis of early and late onset arthralgia or arthropathy,34 we stratified our 
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analysis by age using a cut-off point of 65 years. A two sided p<.05 was considered as 
statistically significant. 
Results 
Baseline characteristics The baseline characteristics of the participants are presented in 
Table 1. Persons with arthralgia were more often women and users of pain medications 
(p<0.001). Genotype frequencies and baseline characteristics did not differ between persons 
aged 65 years or younger and those aged 65 years or over, and between persons who had data 
on genotype, clinical and radiographic findings compared to others (data not shown). In 
persons with arthralgia, the number of joints with pain for each subject ranged from 1 to 10 
(median=2). Allele and genotype proportions were in Hardy Weinberg equilibrium overall 
and in persons without arthralgia. The baseline characteristics did not differ across the HFE 
genotypes, except that H63D homozygotes aged 65 years or younger were significantly 
(p<0.02) more often user of pain medications and/or physiotherapy than non-carriers (data not 
shown). 
Table 1. Participants’ characteristics by age and presence of arthralgia† 
 Age ≤ ҏ65 years Age > 65 years 
 With arthralgia No arthralgia p-value* With arthralgia No arthralgia p-value*
Characteristics (n=473) (n=493)  (n=526) (n=555)  
Age (years) 60.3±0.1 60.3±0.1 0.2 71.2±0.2 70.8±0.2 0.7 
Women (%) 58.9 41.1 <0.001 63.7 42.7 <0.001 
Body mass index 
(kg/m2)‡ 
26.1±0.2 26.3±0.2 0.1 25.9±0.2 26.3±0.2 0.4 
User of painkiller or 
physiotherapy (%) 
69.8 30.2 <0.001 68.7 31.3 <0.001 
Frequency of HFE 
mutations (%) 
      
 C282Y 6.2 6.3 0.9 5.5 6.0 0.3 
 H63D 16.7 15.7 0.3 14.4 15.5 0.4 
†Plus-minus values are means± standard errors. ‡Body mass index was calculated as weight in kilograms 
divided by the square of height in meters.*p value for comparison of subjects with and without arthralgia.  
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HFE mutations and arthralgia Overall, H63D homozygotes had significantly a higher 
frequency of polyarthralgia (OR 1.6; 95% CI 1.0 to 2.6; p<0.05) and oligoarthralgia (2.3;  
1.2 to 4.4; p<0.01) compared to non-carriers. The frequency of arthralgia was not increased in 
C282Y or H63D heterozygotes compared to non-carriers. Table 2 presents the analysis 
stratified by age. H63D homozygotes aged 65 years or younger had a significantly higher 
frequency of arthralgia (3.1; 1.3 to 7.4; p<0.01) compared to non-carriers. Figure 1A shows 
that H63D homozygotes had a significantly increased risk of arthralgia at hands (4.0; 1.4 to 
11.7; p<0.001), hips (3.2; 1.0 to 10.8; p<0.05) and knees (3.5; 1.2 to 10.1; p<0.05). In those 
aged 65 years or over, the frequency of arthralgia did not differ by HFE genotypes (Table 2 
and Figure 1B). 
Table 2. The frequency of arthralgia at any joint site by HFE genotypes 
 Age ҏ≤ҏ 65 years Age > 65 years 
HFE genotypes n Percent OR (95% CI)† n Percent OR (95% CI)† 
Non carriers  847 49.1 1.0 (Reference)  959 49.0 1.0 (Reference) 
Heterozygotes  116 47.4 0.9 (0.6-1.4)  119 47.5 0.9 (0.6-1.3) 
C282Y  
Homozygotes  3 66.7 1.5 (0.1-17.2)  3 33.3 0.6 (0.1-6.7) 
Non carriers  679 49.2 1.0 (Reference)  791 49.6 1.0 (Reference) 
Heterozygotes  261 46.0 0.9 (0.6-1.2)  257 45.5 0.9 (0.6-1.1) 
H63D 
Homozygotes  26 73.1 3.1 (1.3-7.4)*  33 51.5 1.0 (0.5-2.1) 
Abbreviation: OR, Odds ratios compare the prevalence of arthralgia among subjects heterozygous or 
homozygous for the C282Y or H63D mutations to that of non-carriers, calculated using logistic 
regression analysis while adjusting for age and gender; CI, Confidence interval. *p<0.01 for 
comparison with non-carriers. 
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Figure 1. Odds ratio for arthralgia in H63D homozygotes aged (A) ≤ 65 and (B) > 65 years. 
Figures within the brackets indicate 95 percent confidence intervals. 
HFE mutations and chondrocalcinosis Overall, there was no significant difference in the 
frequency of chondrocalcinosis at hip or knee joints by HFE genotypes. When stratifying by 
age (Table 3), H63D homozygotes aged 65 years or younger had a significantly higher 
frequency of chondrocalcinosis compared to non-carriers (4.7; 1.2 to 18.5; p<0.02). 
HFE mutations and radiographic osteoarthritis Overall, the number of joints with 
osteophytes at hands increased significantly with the numbers of H63D mutation (p for 
trend<0.01). Among persons aged 65 years or younger, the number of joints with osteophyte 
was increased in H63D heterozygotes (mean 5.2± standard error 0.4; p<0.03) or homozygotes 
(6.1±1.0; p=0.08) compared to non-carriers (4.4±0.3; p for trend<0.03; Table 4). In H63D 
homozygotes compared to non-carriers, the number of hand joints with space narrowing 
(2.8±0.5 versus 1.0±0.1), or with radiographic osteoarthritis (4.4±0.7 versus 2.0±0.2) were 
significantly increased. Again, no relation to HFE genotypes was found in persons aged 65 
years or over. We found no significant difference in number of osteophytes, presence of joint 
space narrowing or radiographic osteoarthritis across HFE genotypes at either hip or knee  
joints (data not shown). 
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Table 3. The frequency of chondrocalcinosis at hip or knee joints by HFE genotypes. 
  Age ≤ 65 years Age > 65 years 
HFE genotypes n Percent OR (95% CI)* n Percent OR (95% CI)*
Non carriers  469 4.5 1.0 (Reference) 516 7.4 1.0 (Reference)
Heterozygotes 74 2.7 0.7 (0.1-2.9) 60 8.3 1.2 (0.1-3.3) 
C282Y 
Homozygotes 2 0.0 - 2 0.0 - 
Non carriers  372 4.0 1.0 (Reference) 434 6.9 1.0 (Reference)
Heterozygotes 146 4.1 1.1 (0.4-2.8) 147 10.2 1.8 (0.9-3.5) 
H63D 
Homozygotes 14 21.4 4.7 (1.2-18.5)* 19 0.0 - 
Abbreviation: OR, Odds ratios compare the prevalence of arthralgia among subjects heterozygous or 
homozygous for the C282Y or H63D mutations to that of non-carriers, calculated using logistic 
regression analysis while adjusting for age and gender; CI, Confidence interval. *p<0.02 for 
comparison to non-carriers. 
 
Table 4. Number of hand joints with osteophytes, joint space narrowing or radiographic osteoarthritis
(ROA) by HFE genotypes.† 
 Osteophytes Joint space narrowing ROA‡ 
 
Age ≤ 65 
years 
Age > 65 
years 
Age ≤ 65 
years 
Age > 65 
years 
Age ≤ 65 
years 
Age > 65 
years 
HFE genotypes n  n      
Non carriers 590 5.0±0.3 534 6.3±0.4 1.4±0.1 1.6±0.2 2.4±0.5 3.3±0.4
Heterozygotes 78 5.5±0.6 71 5.8±0.7 1.9±0.3 1.2±0.4 2.3±0.4 2.6±0.6
C282Y 
Homozygotes 3 5.3±2.5 3 2.3±4.9 0.2±1.5 2.3±3.0 - 3.6±4.2
Non carriers 466 4.4±0.3 446 4.7±1.6 1.0±0.1 2.0±1.0 2.0±0.2 3.5±1.4
Heterozygotes 184 5.2±0.4* 142 4.7±1.7 1.2±0.2 1.6±1.0 2.4±0.3 3.2±1.4
H63D 
Homozygotes 18 6.1±1.0 18 4.9±2.0    2.8±0.5** 1.5±1.2    4.4±0.7** 2.8±1.7
†Figures are mean± standard error, calculated using univariate linear regression analysis while adjusting 
for age and gender. ‡ROA was diagnosed for any joint with a Kellgren score 2 or higher. *p<0.03, 
**p<0.01 for comparison with non-carriers. 
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HFE mutations and Heberden’s nodes Overall, 21.5 percent of H63D homozygotes (n=51) 
compared to 16.9 percent of non-carriers (n=1316) had Heberden’s nodes (OR 2.1; 95% CI 
1.1 to 3.9; p<0.02). Again, H63D homozygotes aged 65 years or younger had a significantly 
(p<0.01) higher frequency of Heberden’s nodes (3.1; 1.3 to 12.8; Table 5). The frequency of 
Heberden’s nodes by HFE genotypes did not differ in H63D or C282Y heterozygotes, or in 
those aged 65 years or over. 
Compound heterozygotes and outcomes Compound heterozygotes aged 65 years or 
younger were associated with none of the outcomes under the study. Compound 
heterozygotes aged 65 years or over had a significantly higher frequency of polyarthralgia 
(2.9; 1.0 to 9.3; p<0.05), increased number of osteophytes at knee joints in the overall analysis 
(4.9±0.6 versus 2.2±0.1; p<0.01) and in those aged 65 years or over (6.9±1.2, n=5 versus 
2.4±0.1, n=374; p<0.01). At hands, the number of joints with osteophytes, space narrowing or 
radiographic osteoarthritis and the frequency of Heberden’s nodes did not significantly differ 
between compound heterozygotes aged 65 years or over and non-carriers.  
Table 5. The frequency of Heberden’s nodes by HFE genotypes.*  
 Age ≤ 65 years Age > 65 years 
HFE genotypes n Percent OR (95% CI) n Percent OR (95% CI) 
Non carriers  701 19.7 1.0 (Reference)  835 19.2 1.0 (Reference) 
Heterozygotes  107 15.0 0.9 (0.5-1.7)  110 11.8 0.6 (0.3-1.0) 
C282Y 
Homozygotes  2 50.0 4.0 (0.2-65.3)  2 0.0 - 
Non carriers  637 16.0 1.0 (Reference)  726 17.9 1.0 (Reference) 
Heterozygotes  246 16.3 1.0 (0.7-1.6)  240 19.6 1.1 (0.7-1.6) 
H63D 
Homozygotes  23 34.8 3.1 (1.3-12.8)*  28 25.0 1.4 (0.6-3.5) 
Abbreviation: OR, Odds ratios compare the prevalence of arthralgia among subjects heterozygous or 
homozygous for the C282Y or H63D mutations to that of non-carriers, calculated using logistic 
regression analysis while adjusting for age and gender; CI, Confidence interval. *p=0.02 for 
comparison with non-carriers. 
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HFE mutations, arthralgia and mortality To explore why we found a strong relation of 
H63D homozygosity to arthralgia and arthropathy before age 65 years but not later in life, we 
studied the mortality in H63D homozygotes. In persons aged 65 years or younger, H63D 
homozygotes with arthralgia at any joint had a 4 (95% CI 1.4 to 11.7; p<0.01) fold increased 
risk of mortality compared to non-carriers without arthralgia during the follow up period. 
C282Y or H63D homozygotes and clinical arthropathy When the radiographs of H63D 
homozygotes (n=59) or C282Y (n=6) were re-examined by a rheumatologist specifically for 
the presence of pathology related to hereditary hemochromatosis, most subjects had two or 
more joints affected with multiple pathologies such as osteophytes, sclerosis, joint space 
narrowing and calcification (Figure 2). The clinical findings with regard to the features that 
did not discuss earlier are summarized in Table 6. Only in three persons (4.6 percent), the 
radiographic findings were recognized as compatible with hereditary hemochromatosis. Of 
C282Y homozygotes, three persons aged less than 65 years had osteoarthritis at hands and 
among them one underwent total hip replacement. Among the others, one had mild 
generalized osteoarthritis, another one had articular calcification, and the last had a moderate 
spondylophytosis. 
Table 6. Radiographic findings in subjects homozygous for the HFE C282Y or H63D mutations.* 
 Age ≤ 65 years Age > 65 years 
Radiographic findings Hips Knees Hands Spine Hips Knees Hands Spine
C282Y homozygotes (n=6) (n=3) (n=3) 
 Spondylophytes - - - 100.0 - - - 100.0
 
Articular or periarticular 
calcifications 
33.3 33.3 0.0 0.0 0.0 33.3 0.0 0.0 
 Subchondral bony sclerosis 33.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Subchondral bony cysts 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
H63D homozygotes (n=59) (n=25) (n=34) 
 Spondylophytes  - - - 96.0 - - - 50.0
 
Articular or periarticular 
calcifications  
20.0 16.0 20.8 16.0 0.0 6.0 37.0 13.3
 Subchondral bony sclerosis  16.0 4.0 20.8 12.0 17.9 0.0 29.6 6.6 
 Subchondral bony cysts  8.0 0.0 4.0 0.0 0.0 3.0 14.3 0.0 
*Figures are percentages. 
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HFE mutations and clinical hemochromatosis None of C282Y or H63D homozygotes, or 
compound heterozygotes had received a diagnosis of clinical hemochromatosis from their 
general practitioner or any other physician at the baseline or during the follow up. 
Figure 2. Arthropathy in 
H63D homozygotes.  
2a shows a knee with 
chondrocalcinosis, arrows 
show a marked deposition of 
calcium crystal in synovial 
cartilage. 2b shows 
osteoarthritis at hands 
accompanied by clear 
calcium crystal deposition 
() in cartilage of bone and 
synovium in distal 
interphalangeal, osteophytes 
(h) in metacarpophalangeal 
joints. 2c shows a severe 
osteoarthritis in both hips 
with large osteophytes (h), 
severe joint space narrowing 
particularly in right joint (t), 
large subchondral cysts (Z) 
in femoral neck and left 
trocanter, stigma of 
therapeutic osteotomy for 
osteoarthritis (x). 
 
2a 
2b 
2c 
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Discussion 
Main findings This study evaluated the relation between HFE and arthropathy in the general 
population. Overall, we found that H63D homozygotes had more often arthralgia. In persons 
aged 65 years or younger, H63D homozygosity was consistently associated to arthralgia at 
multiple joint sites, chondrocalcinosis, radiographic osteoarthritis at hands, and Heberden’s 
nodes. H63D homozygotes used more often pain medication. We found that H63D 
homozygotes with arthralgia had a higher mortality. We found no association to C282Y 
homozygotes or heterozygotes. In persons aged 65 years or over, compound heterozygosity 
was associated to arthralgia, chondrocalcinosis at hip and osteophytes at knee joints. 
Advantages and limitations of the current study A point of concern for population-based 
studies of genetic factors is the probability of bias due to population admixture.35, 36 The 
Rotterdam Study consists of an ethnically homogenous population. Typing of multiple genetic 
markers has not revealed any evidence for the presence of population admixture.37 Another 
source of bias may be observer related misclassification. All radiographs were scored blinded 
to other clinical data and genotyping. Therefore, the occurrence of spurious associations due 
to population admixture or a selective misclassification is unlikely. The major strength of our 
study is its population-based design. Most studies on the HFE gene mutations have been on 
clinical based samples. Another strength of our study was the use of several related clinical 
(subjective) and radiographic (objective) outcomes. 
C282Y, H63D and arthropathy We observed that H63D homozygotes had a consistent 
increased risk of early onset arthralgia and arthropathy at multiple joint sites. In line with this 
finding, H63D homozygotes used more often pain medication in our study population. We 
found no relation to arthropathy in C282Y homozygotes or heterozygotes for C282Y. The 
effect of C282Y on iron metabolism is much stronger than that of H63D,18, 38 and thus the risk 
for hemochromatosis is the highest.15 Therefore, one may expect a stronger association to 
arthropathy in C282Y carriers. There are a number of explanations why we failed to find this 
trend. One may speculate that the numbers of C282Y homozygotes were too few to draw a 
definite conclusion in our study. However, this finding is not unique to our population. Others 
also found no relation to arthralgia or joint pathology in carriers of C282Y.19-21 One of these 
studies composes over 40000 persons who were screened for HFE and showed no relation of 
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arthralgia to C282Y homozygosity (n=128) or compound heterozygosity (n=616).19 Together, 
these findings suggest that C282Y is not a determinant of arthralgia in the general population. 
One study reported a small relation of C282Y to chondrocalcinosis,23 and another study 
reported a relation between C282Y heterozygosity and late onset hand osteoarthritis.19 For 
C282Y heterozygosity we found an effect on arthralgia and arthropathy only in compound 
heterozygotes for C282Y and H63D after age 65 years. These findings suggest that C282Y 
heterozygosity may have a late effect, whereas H63D homozygosity showed an early effect in 
our study. 
From a pathological prospect, the question is whether the levels of iron determine the 
relationship between H63D and early onset arthropathy. In fact, there is clinical support for 
the view that the iron overload may not be the main determinant of arthropathy as arthropathy 
shows a poor response to phlebotomy,2 neither did arthropathy show a relation to iron 
concentration in the liver,3 nor to levels of serum iron or ferritin in our population (Data not 
shown). Moreover, arthropathy can occur with moderate iron overload,1 and is uncommon in 
other forms of iron storage diseases,39 suggesting the arthropathy may not be explained 
directly by iron overload.2,3,8 Further research will be needed to determine the precise 
mechanism by which H63D may affect the risk of arthralgia and arthropathy. The report on 
the relation between H63D and rheumatoid arthritis,40 the consistent relation of H63D to 
arthralgia at multiple joint sites, to Heberden’s nodes, which represents an inflammatory 
component in pathogenesis of osteoarthritis,29,41 to chondrocalcinosis, an inflammatory 
mediated condition,12 and to early onset hand osteoarthritis suggest an alternative mechanism 
i.e. the involvement of an inflammatory component in H63D associated arthropathy. 
Understanding the underlying pathologic process may provide new targets for intervention in 
arthropathy associated to hemochromatosis. 
Clinical implications In the present study, H63D homozygosity was associated to arthralgia 
at multiple joint sites and arthropathy. Earlier, we have shown that C282Y and H63D 
homozygotes had higher levels of serum iron and ferritin in the same study population.18 
However, these persons did not have diabetes mellitus,42 a disease associated to 
hemochromatosis. But those HFE homozygotes who smoked or had hypertension, had a 
higher risk for atherosclerosis or stroke.25 C282Y or H63D homozygotes or compound 
heterozygotes had no other complaint to the treating physicians recognized as 
hemochromatosis; and thus did not have a clinical diagnosis of hemochromatosis. This 
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suggests that carriers of H63D may initially presents with arthropathy perhaps together with 
excess iron but without other associated diseases of hereditary hemochromatosis like diabetes 
mellitus, or liver pathology. As a result at the early stages and in the absence of typical 
clinical features, the disease may remain undiagnosed or be misdiagnosed and thus untreated. 
Untreated, disease may progress to irreversible complications like liver diseases,5 or may lead 
to cerebro- cardiovascular events like stroke,25 leading to early death. In this respect, the 
significant higher mortality in a subgroup of H63D homozygotes with arthralgia aged 65 
years or younger is of concern. Further, the early mortality may explain why the association 
of H63D homozygosity to arthralgia or arthropathy is stronger early in life and weak in those 
older than 65 years. Further studies are necessary to translate our findings into clinical and 
public health practice. 
Conclusions Taken together, our findings suggest that H63D may explain at least in part the 
early onset arthropathy in the general population. Although this remains to be confirmed by 
others, our observation suggests that testing for HFE mutations in patients with arthralgia 
aged less than 65 years may be clinically relevant. 
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Abstract 
The H63D mutation in the hemochromatosis gene (HFE) has been associated to pain and 
osteoarthritis at hand joints, and to mortality in the general population. We investigated the 
relation between H63D mutation, Heberden’s nodes, and their joint effect on overall and 
cause-specific mortality. Within the total population of the Rotterdam Study, a population-
based cohort study of 7983 persons aged 55 years or over, 2332 randomly drawn subjects 
have been genotyped for the H63D mutation. Participants were followed up to 13.6 years. 
Cox proportional regression analysis was used to estimate the risk of mortality (Hazard ratio; 
HR) and all analyses were adjusted for age and gender. Overall, no relation was found 
between mortality and the HFE H63D genotypes. The presence of Heberden’s nodes was 
significantly related to a modest increase in mortality (HR 1.3; 95% CI 1.0 to 1.6, p≤0.05). 
Persons homozygous for the H63D mutation with Heberden’s nodes had a substantial increase 
in mortality risk compared to subjects homozygous for the wild type allele without 
Heberden’s nodes (HR 2.7; 95% CI 1.2 to 5.7, p≤0.01). This was explained by an increase in 
mortality risk due to stroke (HR 4.0; 1.2 to 12.9, p≤0.05). Persons homozygous for H63D 
with Heberden’s nodes are characterized by increased levels of C-reactive protein (CRP) in 
serum (p<0.001). Increased levels of serum CRP were not found in those with Heberden’s 
nodes who were not homozygous for the H63D mutation. The increased inflammatory state in 
carriers may explain in part the increased mortality due to stroke. Our study suggests that 
inflammation may explain the increased risk of mortality in H63D homozygotes with 
Heberden’s nodes. 
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The common HFE H63D mutation has been associated to hand osteoarthritis, a common 
complaint in hemochromatosis patients.1-3 In a previous study,4 we found that H63D 
homozygotes with arthralgia are at an increased risk of early mortality. Further we found that 
Heberden’s nodes are more prevalent in persons homozygous for this mutation.4 We 
hypothesized that H63D homozygosity may be associated with a high state of inflammation 
based on evidence that the prevalence of Heberden’s nodes, an inflammatory associated 
condition, was higher in HFE H63D homozygotes in our previous study.4 Consequently, 
patients homozygous for the H63D mutation with Heberden’s nodes are expected to be at 
increased risk of mortality due to increased inflammation. Within a population-based follow 
up study of 7983 persons aged 55 years or over, we tested whether the H63D homozygosity 
and Heberden’s nodes lead to increased mortality due to increased levels of inflammation. We 
examined the relation between the H63D mutation, Heberden’s nodes to the levels of serum 
CRP in a population-based study, the Rotterdam Study. 
Methods 
Population The present study was carried out within the framework of the population-based 
Rotterdam Study, a cohort study of major chronic diseases in the elderly. The medical ethics 
committee of the Erasmus Medical Center has approved the study, and informed consent was 
obtained from all the participants. The design and objectives of the study have been described 
elsewhere.5 In brief, 7983 (response rate 78 percent) inhabitants of the district of Ommoord in 
Rotterdam aged 55 years or over participated in the study. Baseline examinations took place 
between 1990 and 1993 by means of structured interview using a standardized questionnaire. 
Participants were followed up to 13.6 years. From the total population, 2332 randomly drawn 
subjects were genotyped for the HFE C282Y and H63D mutations. 
Assessment of Heberden’s nodes During the visit to the research center, trained study 
physicians examined the hand of the participants for the presence of Heberden’s nodes. 
Within the random cohort (n=2332), clinical data on the presence or absence of Heberden’s 
nodes were available for 2005 subjects. 
Assessment of mortality Information on the vital status and cause of death of all participants 
was obtained at regular intervals from municipal health authorities in Rotterdam. Causes of 
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death were coded according to the ICD-10 system.6 For the cause specific study, we focused 
on the three major causes of death i.e. cancer defined as code C00 to D48, coronary heart 
disease as code I20 to I25.9, I70, I70.9, and cerebrovascular disease as code I60 to I69.4. 
Mortality data was available for all subjects within the random cohort. For 1664 persons the 
data on H63D genotypes, Heberden’s nodes and mortality was available. 
Measurement of serum CRP Blood samples were collected on the day of baseline 
examinations by venepuncture. Serum CRP (mg/dL) was quantified by nephelometric method 
using the Beckman Coulter High Sensitivity C-Reactive Protein reagent on the fully 
automated IMMAGE® Immunohistochemistry System. Within the random cohort, 
measurement of the levels of serum CRP was successful for 1940 subjects.  
HFE genotyping Genomic DNA was extracted from a frozen buffy coat using the salting out 
protocol as described elsewhere.7 Mutation analysis was performed as described previously8 
and was successful for both mutations in 2122 subjects. Subjects with the C282Y mutation 
(n=253) were excluded from the present study. The remaining 1869 subjects were 
homozygous for the wild type allele or carriers of the H63D mutation. For 1559 subjects 
H63D genotyping, amount of Heberden’s nodes and measurement of CRP levels were 
available. Allele and genotype frequencies were in Hardy Weinberg equilibrium. 
Data analysis Presence of Heberden’s nodes at the distal interphalangeal joint at both hands 
was considered as a dichotomous variable. The H63D mutation was coded as 0 (wild type 
homozygotes i.e. H63D non-carrier), 1 (H63D heterozygous), or 2 (H63D homozygous). To 
study the joint effect of the H63D mutation and Heberden’s nodes on mortality as well as the 
levels of serum CRP, we stratified the random cohort into four categories. The first category 
consisted of subjects homozygous for the wild type allele who did not have Heberden’s nodes 
(the reference group), the second category of H63D homozygotes without Heberden’s nodes, 
the third category of wild type homozygotes with Heberden’s nodes, and the last category of 
H63D homozygotes with Heberden’s nodes. Independent t, ANOVA and chi-square tests 
were used to compare means and frequencies. Cox proportional regression analysis was used 
to estimate the risk (Hazard ratio; HR) of mortality in carriers of H63D compared to subjects 
homozygous for the wild type allele. All analyses were adjusted for gender and age (years) at 
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the baseline examination. A two tailed p-value <0.05 was considered as statistically 
significant. 
Results 
Table 1 shows the baseline characteristics of the study population. The mean (±S.E.) age of 
the random cohort at the baseline examination was 66.5 (±0.1) years and participants were 
more often women (54.0 percent). Overall 19.6 percent of subjects had Heberden’s nodes. 
Heberden’s nodes were significantly (p=0.001) more often present among women 
(24.6 percent) than men (13.9 percent). The overall population risk of mortality was 27.1 
percent during the follow-up period. Table 2 presents the mortality by H63D genotypes and 
Heberden’s nodes. H63D by itself was not associated to increased risk of mortality. The 
mortality in persons with Heberden’s nodes was modestly but significantly (p<0.05) increased 
(Table 2).  
Figure 1 shows the joint effect of the H63D mutation, and Heberden’s nodes on 
mortality. The risk of mortality of H63D was only significantly (p<0.01) increased for 
persons who were homozygous and had Heberden’s nodes compared to wild type  
Table 1. Baseline characteristics of the study population. 
 Overall H63D genotypes 
Characteristics  
Wt/Wt 
homozygotes
H63D/Wt 
heterozygotes 
H63D/H63D 
homozygotes 
Number of participants 2122 1314 496 59 
Age (years) 66.5±0.1 66.2±0.2 66.0±0.3 66.8±0.9 
Women (%) 54.0 53.6 49.2 50.8 
Heberden's nodes (%) 19.6 19.1 20.1 29.4 
Body mass index (kg/m2)  26.1±0.1 26.2±0.1 26.1±0.2 25.8±0.1 
Plus minus figures represent mean (±S.E.).  
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Table 2. Mortality by (a) HFE H63D mutation or (b) Heberden's nodes. 
 n Percent of Death HR (95% CI) 
a. The H63D genotype    
Wt/Wt homozygotes  1314 28.4 1.0 (Reference) 
H63D/Wt heterozygotes 496 25.6 0.9 (0.8-1.1) 
 
H63D homozygotes  59 33.9 1.1 (0.7-1.8) 
b. Heberden's nodes     
 Absent 1611 22.8  1.0 (Reference) 
 Present  394 26.9  1.3 (1.0-1.6)* 
HR, hazard ratios were adjusted for age and gender. *p<0.05. 
homozygotes without Heberden’s nodes (HR 2.7; 1.2 to 5.7). The mortality in this subgroup 
was also significantly increased compared to the other subgroups. H63D homozygotes with 
Heberden’s nodes died significantly (p<0.05) more often of stroke compared to wild type 
homozygotes without Heberden’s nodes (4.0; 1.2 to 12.9). No other association was found to 
other causes of death i.e. cancer, or coronary heart disease (data not shown).  
Figure 2 shows the relation between H63D genotypes, Heberden’s nodes and their 
joint effects on CRP levels at the baseline examination. Levels of serum CRP were increased 
in persons homozygous for H63D mutation (mean±S.E. 6.1±0.9, n=46) compared to persons 
homozygous for the wild type allele (2.7±0.2, n=1208). However, this difference was not 
statistically significant (Figure 2, Graph A). When the levels of serum CRP were analyzed by 
Heberden’s nodes, persons with Heberden’s nodes showed a modest non-significant increase 
in the levels of serum CRP (3.5±0.3, n=365) compared to those without this condition 
(2.7±0.1; n=1496; Figure 2, Graph B). H63D homozygotes with Heberden’s nodes had 
increased serum levels of CRP (15.5±1.6; n=13) compared to those homozygous for the wild 
type allele who did not have Heberden’s nodes (2.8±0.2; n=1220; Figure 2, Graph C). 
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Figure 1. Mortality by possible combinations of homozygosity for the HFE H63D mutation 
and Heberden's nodes. Figure within the brackets present 95 percent confidence interval of the 
corresponding hazard ratio. Significance: *p<0.03; **p<0.01. 
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Figure 2. Levels of serum C-reactive protein (CRP) by (A) H63D genotypes, (B) 
Heberden’s nodes and (C) combination between H63D and Heberden’s nodes. Wt/Wt 
represents persons homozygous for the wild type allele; Non-DD represents persons non-
homozygous for H63D, D/Wt represents persons heterozygous for H63D, and D/D 
represents persons homozygous for H63D. Error bars represent the standard error of 
means. ***Significance compared to the reference group: p<0.001. 
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Discussion 
Overall, the H63D mutation was not associated to mortality in our population-based study. 
We found that subjects with Heberden’s nodes had a slight but significantly higher risk of 
mortality. Persons homozygous for the H63D mutation with Heberden’s nodes were at a 
significant increased risk of mortality mostly due to cerebrovascular events and had increased 
levels of serum CRP at the baseline examination compared to subjects homozygous for the 
wild type allele without Heberden’s nodes. 
This is the first study that addressed the role of HFE and inflammation in relation to 
mortality. In our population, the H63D mutation was not associated to mortality. This finding 
is consistent with several other studies.9-12 In line with this finding, others also found no 
decrease in prevalence of the H63D mutation in elderly people.9,10 Overall, our findings 
together with those of others,9-12 suggest that the H63D mutation by itself is not associated to 
mortality. 
In the present study, we observed that Heberden’s nodes were associated to mortality 
due to cerebrovascular events. This finding may echo other studies13,14 which found a relation 
between osteoarthritis at distal interphalangeal joints13 or generalized osteoarthritis14 and 
mortality due to cardiovascular events, and adverse risk profile for coronary heart disease.15 
To our knowledge, no previous study investigated the relationship between Heberden’s nodes 
and mortality. As H63D was associated with Heberden’s nodes in our study population,4 we 
tested whether Heberden’s nodes modify the relation between H63D and mortality. We found 
a significant increased risk of early mortality due to cerebrovascular event i.e. stroke in H63D 
homozygotes with Heberden’s nodes. Heberden’s nodes has been known as an inflammatory 
associated condition, we tested a hypothesis that the high inflammatory status in H63D 
homozygotes compared to non-carriers may explain the relation between H63D, Heberden’s 
nodes and their positive interaction with an early mortality due to stroke. We observed that 
H63D homozygotes as well as Heberden’s nodes had an increase in levels of serum CRP. But, 
H63D homozygous with Heberden’s nodes had a significant increase in levels of serum CRP.  
In summary, our epidemiological findings suggest that H63D is not independently 
associated to early mortality. Our findings suggest that subjects homozygous for the HFE 
H63D mutation who also have Heberden’s nodes before age 65 years are at increased risk of 
early mortality due to cerebrovascular events. H63D homozygosity has a joint effect with 
Heberden’s nodes and coincides with higher inflammatory status that may explain increased 
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mortality due to cerebrovascular events. Our findings may have a potential preventive value 
in clinical practice but remains to be confirmed by others. 
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Abstract 
Serum bilirubin is an important antioxidant that is found at increased levels in hereditary 
hemochromatosis patients. We hypothesized that increased levels of serum bilirubin may play 
a protective role against oxidative stress induced by iron overload in carriers of mutations in 
the hereditary hemochromatosis gene (HFE). We studied the relation between serum total 
bilirubin, serum iron levels, HFE C282Y and H63D mutations, and mortality. The study was 
conducted in 2332 randomly selected subjects from the Rotterdam Study, a population-based 
follow up study of people aged 55 years or over. Serum bilirubin levels were significantly 
correlated with serum ferritin (Pearson’s correlation coefficient (r)=0.2, p<0.05), iron (r =0.4, 
p<0.001) and transferrin saturation (r=0.4, p<0.001). Carriers of the HFE mutations had 
higher levels of bilirubin compared to wild type homozygotes. The relation was the strongest 
in H63D heterozygotes or homozygotes and C282Y heterozygotes. High levels of serum 
bilirubin were associated with a 2.8 (95% CI 0.9 to 8.8) fold reduction in mortality in H63D 
homozygotes and a 2.2 (1.0 to 4.7) fold reduction in mortality in C282Y heterozygotes. Taken 
together, our data suggest that the high levels of the antioxidant bilirubin may counteract the 
adverse effect of oxidative stress induced by iron overload. This may explain in part the 
reduced penetrance of the HFE mutations. 
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Hereditary hemochromatosis is one of the most common genetic disorders in Caucasians with 
a prevalence rate up to 1 in 200 to 400.1,2 The disease is characterized by iron overload in 
multiple organs.3 In over 80 percent of patients, the disease is explained by mutations in the 
HFE gene.4 The predominant mutation in patients is a single base transition, c.845G→A 
(C282Y), leading to substitution of a cysteine residue by tyrosine at position 282 of the HFE 
protein.4 The second common mutation is the c.187C→G (H63D) transversion leading to a 
substitution of histidine by aspartic acid at position 63 of the HFE protein.4 
While for long the penetrance was thought to be high in C282Y homozygous and 
compound heterozygous, recent studies suggested a low penetrance of clinical disease based 
on hemochromatosis pathology.5 Also the common H63D polymorphism is associated with 
only a mild increase in risk of clinical hemochromatosis.6-8 This raises the question whether 
there are physiological mechanisms in the body that counteract the adverse effects of excess 
iron in carriers. Edwards and colleagues9 reported hyperbilirubinemia in 31 percent of patients 
with hereditary hemochromatosis. These patients did not have signs of hemolysis, or liver 
pathology, one of the most common and lethal disorder in patients with hereditary 
hemochromatosis.10,11 One of the most important pathways through which the HFE mutations 
may lead to chronic disorders is thought to be oxidative stress that is induced by iron 
overload.12,13 Bilirubin, in any sub fractions i.e. conjugated, unconjugated or bound to serum 
albumin, is a strong endogenous antioxidant.13-17 We hypothesized that high levels of bilirubin 
may counteract the high oxidative stress due to excess iron in HFE carriers and may thus 
contribute to the reduced penetrance of HFE mutations. To test this hypothesis, we addressed 
two main research questions in asymptomatic carriers derived from a population-based study, 
the Rotterdam Study. First, we studied the relation between serum iron indices, the HFE 
H63D and C282Y genotypes and serum bilirubin. Second, we evaluated the relation between 
levels of serum bilirubin and mortality in carriers of HFE C282Y and H63D mutations. 
Methods 
From the Rotterdam Study (n=7893), 2332 subjects were randomly selected and 
genotyped for the HFE C282Y and H63D mutations. The design of the Rotterdam Study has 
been described elsewhere.18 In brief, this study is a population-based follow up study of 
inhabitants of the district of Ommoord in Rotterdam aged 55 years or over. The aim of the 
study is to investigate the determinants of chronic and disabling disorders in the elderly. Full 
subjects’ recruitment, data acquisition and baseline examinations took place between 1990 
                                                                                         THE HFE GENE, BILIRUBIN AND MORTALITY 
 
 
 
 109 
and 1993 by means of a structured interview and a physical examination by research 
physicians. The medical ethics committee of Erasmus Medical Center has approved the study 
and written informed consents and permission to retrieve information from medical records 
were obtained from all participants. Participants were followed for 13.6 years. Information on 
the vital status of all participants was obtained at regular intervals from municipal health 
authorities in Rotterdam. The data on hospital admissions and corresponding diagnosis of 
hemochromatosis or other liver diseases were retrieved from medical records of participants’ 
general practitioner and hospitals’ registry databases. From the total cohort genotyped, serum 
iron, ferritin and transferrin saturation were determined in a total of 342 persons. We included 
all subjects with rare genotypes i.e. C282Y homozygotes (n=8) and compound heterozygotes 
(n=51). Further, based on power calculations (α=0.05 and β=0.8) for the other genotypes 
about 70 subjects were selected, i.e. those without any mutation (the wild type homozygotes, 
Wt/Wt, n=74), the H63D heterozygotes (Wt/H63D, n=73), the C282Y heterozygotes 
(Wt/C282Y, n=71), and the H63D homozygotes (H63D/H63D, n=61). 
For 108 men and 124 women serum levels for both iron indices and bilirubin were 
available. For a total of 1394 participants (men 627, women 767) data on vital status, serum 
bilirubin and HFE genotypes were complete. 
At the baseline examination at the research center blood samples were collected by 
venepuncture in the morning. Serum and plasma was separated immediately, and kept frozen 
at –80°C until the laboratory analysis. Genomic DNA was extracted from buffy coat using the 
salting out protocol as described elsewhere.19 The HFE C282Y and H63D mutations analysis 
was performed as described previously.4 Serum total bilirubin (µmol/l) was measured 
according to the protocol of Bartels and Bohmer [1971]. Serum ferritin (µg/l), iron(µmol/l) 
and transferrin (µmol/l) were measured as described elsewhere.20 All measurements were 
done in the same laboratory by the same experienced technicians. 
Serum ferritin levels were not normally distributed therefore they were transformed to a 
logarithmic scale to achieve normality. One-way analysis of variance or t-test was used to 
compare means and the χ2 test was used to compare frequencies between groups. The 
correlation between serum iron indices and serum total bilirubin was estimated using 
Pearson’s correlation coefficients. Median of serum bilirubin was used as the cut-off point to 
categorize the participants into two subgroups of those with high (above median) and those 
with low (below median) serum total bilirubin levels. Cox proportional regression analysis 
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was used to compare the cumulative survival rates in HFE carriers with high to low serum 
total bilirubin levels. As gender determines the penetrance of HFE genotypes all analyses 
were stratified by gender. Continuous variables are reported as mean±the standard error, 
unless otherwise specified. 
Results 
Table 1 summarizes the characteristics of the participants including the HFE genotypes 
frequencies. When comparing the 1394 subjects in whom bilirubin was assessed to those 
without data on serum bilirubin (n=938), we found no significant difference in the 
characteristics listed in Table 1. Mean age in men (66.3±0.3 years) did not differ from that in 
women (66.2±0.2 years). Five percent of the 1394 subject had a history of liver disease and 
none of the participants had received a diagnosis of hereditary hemochromatosis from their 
general practitioner or any other physician at the baseline or during the follow up. Serum 
bilirubin levels, iron indices, alanine aminotransferase, and hemoglobin differed significantly 
between men and women. Overall, HFE genotype or allele proportions were similar for men 
and women and were in Hardy-Weinberg equilibrium. 
The relationship between levels of serum iron indices and serum bilirubin is 
summarized in Table 2. In both men and women, serum iron levels and transferrin saturation 
were significantly correlated with serum bilirubin levels. A significant correlation between 
serum ferritin and serum bilirubin was observed only in women. This can be explained by the 
fact that serum ferritin had the largest standard deviation. 
Figure 1 shows the relation of HFE mutations to serum bilirubin. In the overall 
analysis and in the analysis of men, those heterozygous or homozygous for the H63D 
mutation and those heterozygous for the C282Y mutation had significantly increased levels of 
serum bilirubin compared to those homozygous for the wild type allele. In women 
homozygous for the H63D mutation, levels of serum bilirubin were significantly increased 
compared to those homozygous for the wild type allele. 
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Table 1. Characteristics of participants and HFE genotype frequencies. 
 
Overall 
n=1394 
Men 
n=627 
Women 
n=767 
Age (years) 66.3±0.2 66.3±0.3 66.2±0.2 
Total bilirubin (µmol/l)*† 09.1±0.1 10.1±0.2 08.3±0.1 
Alanine aminotransferase (iu/l)* 19.2±0.3 20.4±0.5 18.2±0.4 
Aspartate aminotranferase (iu/l) 20.7±0.2 21.2±0.3 20.3±0.3 
Hemoglobin* 8.9±0.1 9.3±0.1 8.6±0.6 
Ln serum ferritin (µg/l)† 04.9±0.1 05.0±0.1 04.8±0.1 
Serum iron (µmol/l)* 18.0±0.4 19.3±0.6 17.0±0.5 
Serum transferrin saturation* (%) 30.9±0.7 33.0±1.2 28.9±0.9 
History of liver disease 5.4 % 5.1 % 5.6 % 
HFE genotype frequencies    
Wt/Wt 61.4 % 58.7 % 63.6 % 
Wt/H63D 23.9 % 26.0 % 22.2 % 
Wt/C282Y 9.6 % 10.7 % 8.7 % 
H63D/H63D 2.9 % 3.2 % 2.6 % 
C282Y/H63D 1.9 % 1.1 % 2.5 % 
C282Y/C282Y‡ 0.4 % 0.3 % 0.4 % 
The figures are presented as means± the standard errors or as percentage. †Ln. natural logarihtm 
transformation. ‡Only 4 women and 2 men were homozygous for the C282Y mutation. The numbers 
were too small for meaningful statistical analysis. Comparison between men and women: *p<0.05. 
 
Table 2. Partial Pearson’s correlation coefficients between serum iron indices and total bilirubin.# 
 Overall Men Women 
Ferritin (µg/l) 0.2 * 0.0 0.2 ** 
Iron (ng/l) 0.4 ** 0.4 ** 0.4 ** 
Transferrin saturation (%) 0.4 ** 0.4 * 0.4 ** 
# Correlations were adjusted for age and gender. Significance: *p<0.01; **p<0.001. 
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Figure 2 shows the total mortality for subjects by serum bilirubin levels and HFE 
genotypes. In those homozygous for the wild type allele or heterozygous for the H63D 
mutation, high bilirubin levels were not associated to mortality. In those homozygous for the 
H63D mutation, high bilirubin levels were associated with a 2.8 (95% CI 0.9 to 8.8) fold 
reduction in mortality overall, a 2.1 (0.4 to 12.5) fold reduction in men and a 3.3 (0.7 to 16.7) 
fold reduction in mortality in women. In those heterozygous for the C282Y mutation we 
observed a 2.2 (1.0 to 4.7) fold reduction in mortality overall, a 2.1 (0.7 to 7.1) fold in men, 
and a 1.6 (0.6 to 5.0) fold in women with high bilirubin compared to those with low bilirubin. 
Overall there was no significant difference in mortality among the HFE genotypes regardless 
of levels of bilirubin. 
Discussion 
Our population-based study showed that levels of serum total bilirubin were significantly 
related to serum iron indices and HFE genotypes in both men and women. High serum 
bilirubin levels were associated with a substantial reduction in mortality in those homozygous 
for H63D or heterozygous for the C282Y mutation. 
A limitation of the present study was the lack of information on the conjugated 
fraction of the serum total bilirubin, and on the causes of mortality. The other limitation was 
the number of persons homozygous for C282Y was too low for a meaningful statistical 
comparison. The advantage of our study was its population-based design. 
We found that the HFE mutations are associated with two counteracting metabolites. On the 
one hand, we and others7,21,22 have found that H63D heterozygotes or homozygotes and 
C282Y heterozygotes or homozygotes had higher levels of serum iron, a major oxidant. On 
the other hand, in the present study, we found that H63D heterozygosity or homozygosity and 
C282Y heterozygosity were associated with increased levels of an efficient antioxidant, serum 
bilirubin. This counteracting effect may explain the observed non-penetrance of the HFE 
mutations with regard to chronic disorders that are linked to oxidative stress. 
Serum bilirubin was significantly correlated to serum iron indices. The fact that H63D 
homozygotes had an elevated serum bilirubin level is striking. This genotype is reported to be 
associated with a mild increase in serum iron loading.6,8 However, in our population sample, 
we have reported that this genotype was associated with a very high serum iron level.20 
C282Y homozygosity was significantly associated to high iron levels, but there were not 
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enough subjects to study. In our study population compound heterozygotes had no increase in 
levels of iron and had no increase in levels of serum bilirubin in this study. Altogether, this 
points to the fact that the higher the levels of serum iron, the higher the levels of serum 
bilirubin will be. The mechanism through which bilirubin may be increased in iron overload 
conditions remains to be elucidated. Other factors such as liver diseases and hemoglobin can 
lead to a high bilirubin. But in our study population, these factors did not account for the 
observed associations. One probable mechanism to explain at least part of the variation of 
serum bilirubin by HFE genotypes is the heme-oxygenase pathway. This pathway is an 
inducible anti-oxidant and anti-inflammatory enzymatic complex that catalyses the 
degradation of heme to biliverdin, ferrous iron and carbon monoxide. The induction of the 
heme-oxygenase pathway by oxidant species or iron enhances the production of serum 
bilirubin,14,23-25 and is known as a part of an antioxidant mechanism.26,27 
We further showed that the high bilirubin levels were associated with a reduction in 
mortality in H63D homozygotes or C282Y heterozygotes. This may be due to the fact that the 
deleterious effects of oxidative stress due to excess iron induced by HFE mutations, is 
compensated by an increase in the levels of bilirubin, an antioxidant with well known cardio 
and neuroprotective effects.28-30 In the same line of our findings, Temme and colleagues31 
reported a lower overall, and in particular a lower cancer mortality rate in men with high 
serum bilirubin levels. Taken together, our data suggests that the high levels of bilirubin may 
counteract the adverse effects of oxidative stress induced by iron overload. 
We propose that high bilirubin levels induced by HFE mutations may have a 
protective effect, preventing at least in part the damage induced by iron overload. This may 
explain in part the reduced penetrance of the HFE mutations. Further experimental and 
epidemiological studies are needed to confirm our hypothesis and its clinical implications. 
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Abstract 
Iron plays a crucial role in the pathogenesis of complex disorders such as atherosclererosis, 
neurodegenerative diseases, and cancer. Both iron deficiency and iron overload are common 
public health problems. From a genetic perspective, iron metabolism is a complex trait, in 
which both genetic and environmental factors are involved. The purpose of the present study 
was to estimate the magnitude of genetic influences on serum levels of iron indices including 
iron, ferritin and transferrin saturation in relatives from a recent genetic isolate in the 
Netherlands. Estimation of how much of the variation in the levels of iron and ferritin could 
be explained by additive genetic factors was done using the variance component method 
implemented in Sequential Oligo-genic Linkage Analysis Routines (SOLAR). This study 
included 90 nuclear families with a total of 988 subjects. The proportion of the residual 
phenotypic variance due to additive genetic effects i.e. heritability estimates were 
approximately 0.20 (S.E. 0.06, p<0.0001) for iron, 0.28 (S.E. 0.08, p<0.001) for transferrin 
saturation, and 0.24 (S.E. 0.08, p<0.0001) for ferritin while adjusting for gender and age. 
Further adjustment for serum albumin levels, a significant co-variable of serum iron levels, 
the heritability estimates changed to 0.17 (S.E. 0.07, p<0.0001) for iron, 0.26 (S.E. 0.08, 
p<0.0001) for ferritin, and 0.24 for transferrin saturation (S.E. 0.07, p<0.001). A modest 
proportion of the variance of iron, transferrin saturation, and ferritin can be explained by 
heredity, independent of gender, age and environmental effects. Our results demonstrate the 
influence of both genetic and environmental factors on iron levels.  
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Iron is a crucial component of biochemical reactions.1, 2 High and low levels of body iron are 
associated with common human diseases.1-5 To maintain iron levels within the normal limits 
and thus prevent pathologic consequences of iron excess or deficiency, iron haemostasis 
evolved as a complex and tightly coordinated process in which numerous genes and 
environmental factors are involved.1, 3, 6 The role of genetics on iron haemostasis is supported 
by investigations that proved iron overload as a heritable disease,7 and identified several 
genes involved in iron metabolism.8-12 Arthropathy is one of the most common complaint in 
hemochromatosis patients.1-3 This raised the question whether the genetic factors involved in 
iron haemostasis, are also involved in osteoarthritis.  
Overall, the aim of the present study is to unravel the genetic determinants of iron 
metabolism. Few studies investigated whether levels of serum iron indices are heritable.15, 16 
One twin study15 found no significant heritability for the levels of serum iron. Others have 
estimated, respectively in men and women, 23 and 31 percent heritability for serum iron, 47 
percent for serum ferritin, an iron associated protein, and 21 and 47 percent for transferrin 
saturation.16 The point of concern is that in these studies,15, 16 heritability is overestimated as 
monozygotic twins share more environmental factors than dizygotic twin pairs to which they 
are compared. This may confound the heritability estimations. One approach to overcome this 
problem is the use of an extended pedigree, which also includes second and third degree 
relatives who do not share a common environment. 
Within a recent genetic isolate in the Netherlands, we investigated the magnitude of 
genetic and environmental influences on levels of serum iron and ferritin in 988 individuals 
related to each other in one extended pedigree. Next, we assessed the phenotypic, genotypic 
and environmental correlation between the studied serum iron indices. 
Methods 
Population This study was carried out within a family-based study of 2500 inhabitants of a 
genetically isolated community in the Southwest region of the Netherlands, the Erasmus 
Rucphen Families (ERF) study. The aim of the ERF study is to unravel the genetic 
determinants of several common complex disorders. The target population was founded in the 
middle of the 18th century by about 150 people and was characterized with minimal inward 
migration (less than 5 percent) and considerable population growth. Since 1848, the 
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population expanded to 20000 inhabitants scattered over 8 adjacent villages. Genealogical 
data on this population is currently available including over 63000 individuals. The medical 
ethics committee of the Erasmus Medical Center Rotterdam has approved the study. Written 
informed consent was obtained from all participants.  
Participants’ selection For the purpose of the ERF study, twenty couples, who had at least 6 
children from 1880 to 1900, were identified with the help of genealogical record of the church 
and municipality. Each of these couples could be traced back to one or more of the 10 couples 
who lived in middle of the 16th century in this community. All third, fourth and fifth 
generational descendent of these couples and their spouses were invited to participate in the 
study. 
Data collection and measurements Phenotypic data collection, and baseline examination 
have been performed since June 2002 by means of a structured questionnaire. Participants 
were invited for a series of clinical examinations at the research center. In the present study, 
we will focus on the first 988 participants for whom complete phenotypic data have been 
collected. 
At the start of clinical examination, fasting blood samples were drawn by 
venepuncture, which was done between 7:00 and 10:00 o’clock. Serum samples were 
obtained from the whole blood after clotting. Plasma samples were obtained from whole 
blood collected in disodium EDTA. Serum iron (µmol/l) was measured by means of using the 
Ferrozine method, an immuno(chemi)-luminescence assay, using Roche/Hitachi 747 - 400 Kit 
(Roche). Serum ferritin levels (ng/ml) were measured by a two-site chemiluminescencent 
immunometric assay using the Immulite 2000 (Diagnostics Products Corporation). 
Transferrin saturation (%) was calculated as serum iron levels divided by serum total iron 
binding capacity. Plasma albumin was measured according to standardized protocol. For 988 
persons levels of serum iron, and for 957 persons levels of serum ferritin, and for 988 persons 
levels of serum transferrin saturation were successfully measured. For 953 subjects both 
measurements of serum iron levels and ferritin, for 988 subjects both measurements of serum 
iron levels and transferrin saturation, for 953 subjects both measurements of serum transferrin 
saturation and ferritin were available. Height and weight were measured with participants 
dressed in light under clothing and body mass index was calculated as weight divided by 
height square. 
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Data analysis Inbreeding coefficients, the probability that the two alleles at any locus in an 
individual are inherited from a common ancestor i.e. identical by descent, were calculated 
using PEDIG software (http://dga.jouy.inra.fr/sgqa/diffusions/pedig/pedigE.htm). Prior to 
data analyses, levels of serum iron and ferritin were regressed for the baseline variables 
including age, gender, levels of serum albumin, weight and body mass index using stepwise 
multivariate linear regression analysis. To correct for the amount of genetic materials shared 
between relatives, inbreeding coefficient was also included in the model. Age, gender, and 
serum albumin showed a significant association to serum iron indices and were included as 
covariables in the heritability estimation. From the regression model, we explored 
standardized residuals. As these residuals were skewed, we derived natural logarithmic for 
serum iron and ferritin. 
Heritability estimation- A standard maximum likelihood variance decomposition 
techniques was used to partition the phenotypic covariance of the trait among the relatives 
into variance due to additive genetic factors, and variance due to dominance (non additive 
allelic effects) and environmental i.e. random individual-specific components.17-19 This 
approach is implemented in Sequential Oligo-genic Linkage Analysis Routines (SOLAR) 
software. SOLAR calculates heritability, in the narrow sense, as the ratio of the variance 
explained by additive effects of multiple genes to the total phenotypic variance of the trait.17-19 
The significance of the heritability estimate was obtained by comparing a model in which 
additive heritability was estimated with the one that this parameter fixed to zero. The two 
times difference between natural logarithm likelihood values of the two models distribute as a 
chi-squared distribution with one degree of freedom.17 Heritability was first estimated while 
the model was regressed for age, gender, and inbreeding coefficients (model I), and then 
analyses were repeated including serum levels of albumin. The significance between these 
two models was tested using the likelihood-based chi-square statistics. 
Bivariate correlation analysis- The phenotypic correlation between the levels of 
serum iron and ferritin, iron and transferrin saturation, and serum transferrin saturation and 
ferritin were estimated using Pearson’s correlation coefficients (r). To examine the underlying 
determinants of the phenotypic correlation, series of bivariate analyses between serum iron 
and ferritin, between serum iron and transferrin saturation, and between serum ferritin and 
transferrin saturation were performed to estimate the additive genetic and environmental 
correlation.20 Whether the environmental correlation differs significantly from zero, SOLAR 
compares the likelihood of a model in which this correlation was fixed to zero with a model in 
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which environmental correlation was estimated using a likelihood based chi-square test with 
one degree of freedom. The same procedure was performed for genetic correlation. Further, 
we tested whether the genetic correlation between serum iron indices was significantly 
different from the value of 1. This test exploits the pleiotropic genetic effects.21 Pleiotropy 
describes the phenomena that one or a set of related genes with additive effects, explains more 
than one trait. 
Results 
Overall 988 subjects were included in the analysis consisting of 907 first-degree relative pairs, 
659 second degree relatives pairs, and 2370 third degree relative pairs. Table 1 presents the 
baseline characteristics of the study population. Mean (±S.E.) age was 54.46 (±0.47) years. 
The inbreeding coefficient was 0.007 (range 0.58*10-7 to 0.04) in 685 subjects; for the 
remaining subjects (n=368) no inbreeding was detected. Within the total population, 143 
persons (13.58 percent) had a transferrin saturation of higher than 45 percent. Among subjects 
with serum ferritin available (n=958), 10.35 percent had a serum ferritin higher than 300 
µg/L. In total, 34 (3.22 percent) persons had both transferrin saturation higher than 45 percent 
and a serum ferritin level higher than 300 µg/l. These subjects had a significantly higher 
inbreeding coefficient (mean natural logarithm transformed value 4.79±0.51) compared to the 
remaining cohort (3.45±0.09). 
Table 2 presents the components of phenotypic variance of serum iron levels. The 
heritability estimate was 0.20±0.04 (S.E.) while the model was adjusted only for age and 
gender (model I). The hypothesis of no polygenic effects was rejected (p<0.0001). Adjusting 
for serum levels of albumin (model II) further reduced the heritability estimate to 0.17±0.07 
(p<0.001). With regard to ferritin (Table 3), the heritability estimate was 0.24±0.08 in the 
model adjusted for age and gender. The hypothesis of no additive polygenic effects was 
rejected (p<0.0001). In model adjusted for age, gender, and albumin levels, the heritability 
estimate increased to 0.26±0.08. This was statistically significant (p<0.001). With regard to 
the levels of serum transferrin saturation (Table 4), the heritability estimate was 0.28±0.07 in 
the model when adjusting for age and gender. The hypothesis of no polygenic effects was 
rejected (p<0.0001). 
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Table 1. Characteristics of the study population. 
n 988 
Men (%) 40.20 
Age (years) 54.46±0.47 
Body mass index (kg/m2) 31.47±1.25 
Serum albumin (g/dl) 40.30±0.13 
Serum iron (µmol/l) 19.85±0.22 
Median of serum ferritin (ng/ml) 107 (2.84 - 4732.00) 
Serum transferrin saturation (%) 33.12±0.41 
Inbreeding coefficients 0.007 (0.58*10-7 - 0.04) 
Number and type of relative pairs 
 Parent-offspring 371 
 Siblings 563 
 Half siblings 43 
 Avuncular 875 
 Grandparents-grandchild 35 
 Half avuncular 55 
 First cousins 2262 
 Half first cousins 53 
Plus-minus figures represent mean±S.E. 
 
Table 2. Heritability estimates of serum iron. 
Model n 
Additive 
polygenic effect 
(Heritability) 
Random 
environmental 
factors 
Proportion of 
variance explained 
by covariates 
2 log likelihood 
polygenic 
model 
χ2 test 
 
I  988 0.20±0.04** 0.80±0.06 0.04 551.98 - 
II  905 0.17±0.07** 0.83±0.07 0.03 535.55 32.85**
Figure presents mean proportion± S.E. 
Model I. Ln serum iron = {2.98 - 0.01*(age-53.48) - 0.13*female}. 
Model II. Ln serum iron = {3.00 - 0.001*(age-52.10) - 0.12*female - 8.76e-05*(serum levels of 
albumin - 111.49)}.  
p-value: *<0.001; **<0.0001. 
 
                                                                                               HERTITABILITY OF SERUM IRON INDICES 
 
 
 
 
 129
 
Table 3. Heritability estimates for the levels of serum ferritin. 
Model n 
Additive 
polygenic effect 
(Heritability) 
Random 
environmental 
factors 
Proportion of 
variance explained 
by covariates 
2 log likelihood 
polygenic 
model 
χ2 test 
 
I  957 0.22±0.08** 0.76±0.08 0.25 312.95 - 
II  874 0.26±0.08* 0.74±0.08 0.27 274.22 97.46**
Figure presents mean proportion± S.E. 
Model I. Ln serum ferritin = {5.15 + 0.01*(age - 53.42) - 0.91*female}. 
Model II. Ln serum ferritin = {5.13 - 0.01*(age - 51.97) - 0.93*female - 3.52e-05*(serum levels of 
albumin - 113.94)}. 
p-values: *<0.001; **<0.0001. 
 
Table 4. Heritability estimates of levels of serum transferring saturation. 
Model n 
Additive 
polygenic effect 
(Heritability) 
Random 
environmental 
factors 
Proportion of 
variance explained 
by covariates 
2 log likelihood 
polygenic 
model 
χ2 test 
 
I  988 0.28±0.06*** 0.72±0.06 0.04 468.84 - 
II  905 0.24±0.07*** 0.74±0.08 0.04 448.90 39.87*** 
Figure presents mean proportion ±S.E. 
Model I. Ln serum transferring saturation = {3.49 - 0.001(age-53.48) - 0.16*female)}. 
Model II. Ln serum transferring saturation = {3.50 - 3.44*(age-5.10) - 0.15*female - 1.93e-05*(serum 
levels of albumin - 111.49)}. 
p values: ***<0.0001. 
Further adjustment for serum levels of albumin reduced the heritability estimate to 0.24±0.07 
(p<0.001).  
We found significant positive phenotypic correlations between serum iron and ferritin 
(n=953, r =0.21; p<0.001), serum iron and transferrin saturation (n=988, r=0.90, p<0.001), 
and between serum ferritin and transferrin saturation (n=957, r=0.37, p<0.001). There was a 
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substantial genetic correlation between serum iron and ferritin (0.42±0.25), or transferrin 
saturation (0.72±0.07), and between serum ferritin and transferrin saturation (0.75±0.15). 
These estimates differed significantly (p<0.001) from the value of 1. 
Discussion 
Within a large family-based sample from a recent genetic isolate, we investigated the 
influences of genetic, and environmental factors on the variation in the levels of serum iron 
indices. We found that a significant (p<0.001) proportion of the levels of serum iron 
(0.17±0.07), ferritin (0.26±0.08), and transferrin saturation (0.24±0.07) was explained by the 
additive polygenic effects. We observed significant phenotypic correlations between serum 
iron, ferritin, and transferrin saturation, which were explained by significant underlying 
shared genotypic and environmental factors. 
The major advantage of our study was the use of extended families within a genetic 
isolate. The present sample includes also spouses, second and third degree relatives who do 
not live in the same households. This design reduces the confounding of genetic influences by 
shared household, and environmental effects, which is problematic when samples include 
only nuclear families that may inflate the heritability estimates. 
Our study demonstrated a significant heritability for the levels of serum iron, an 
essential element. In our study population, the heritability estimate was 0.17 for iron and 0.24 
for transferrin saturation when the models were adjusted for age, sex and levels of serum 
albumin. Earlier, Whitefield and colleagues (2000),16 reported 20 to 30 percent of the variance 
of the serum iron levels and 33 percent and 47 percent of the variance in transferrin saturation 
could be explained by additive polygenic effects. For serum ferritin, a protein, we found a 
heritability estimate of 0.24 that was increased to 0.26 when correcting for the levels of serum 
albumin. Comparing to the study of Whitefield and colleagues (2000),16 who estimate a 
heritability of 47 percent for serum ferritin levels in both men and women, the heritability 
estimates of serum ferritin levels is lower in the present study. There are several explanations 
for this. First, the finding from the study of Whitefield and colleagues (2000),16 is 
overestimated due to a higher shared environmental factors in monozygotic twin compare to 
dizygotic twins. Our data suggest a modest heritability to serum iron indices while we 
analyzed relatives who share less environmental factors. Second, we did not correct for the 
effect of other proteins, which induce serum ferritin levels. This may lead to an increase in 
random environmental residuals and thus a decrease in the residual heritability estimate. 
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However, the heritability estimates variations between our and the study of Whitefield and 
colleagues (2000)16 is not unique for serum iron indices. Variations in heritability estimates 
across different populations have been previously observed for other complex traits as well.22, 
23 These variations may be regarded as random or explained by differences in designs, data 
analysis techniques, population genetic make up, or environmental components. Together, our 
findings indicate that a modest proportion of body iron contents is explained by additive 
polygenic effects and thus is modestly heritable.  
We found a significant phenotypic correlation between serum iron and ferritin levels. 
This correlation, were significantly modulated by shared environmental factors, as we found a 
significant environmental correlation between the studied traits. Also, bivariate analysis 
showed a genetic correlation between serum iron, ferritin and transferrin saturation levels that 
were significantly different from the value of 1. This finding may indicate a degree of 
pleiotropy for serum iron, ferritin and transferrin saturation. This may be due to the fact that 
levels of serum iron exert the strongest regulation on ferritin and transferrin production.24, 25 
Thus, the gene pool involved in regulation of iron levels, may also regulate ferritin as well as 
transferrin metabolism.  
We confirmed that a modest proportion of the body iron content could be explained by 
heredity, independent of age, gender and environmental effects. 
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5.1. Main findings and their relevance 
Introduction 
In medicine the concern is to cure, and ultimately, is to prevent osteoarthritis pathology in 
susceptible persons and to slow the joint degeneration, in an affected individual. One way is 
to reduce environmental factors such as biomechanical pressure, or other risk factors among 
them obesity, physical activity or repetitive trauma,1-3 and the other way is to identify 
susceptible subjects, and identify individualized effective interventions. The latter approach 
requires the detailed knowledge of the underlying molecular process leading to joint 
destruction, to which understanding the genetic components of osteoarthritis plays a crucial 
role. 
The overall aim of our research project is to identify genes that contribute to 
osteoarthritis. As a part of this project, candidate genes were analysed in relation to 
osteoarthritis in subpopulations of the Rotterdam Study. We investigated the relationship 
between two candidate genes i.e. the gene encoding the alpha domain of collagen type IX 
(COL9A1) and the hereditary hemochromatosis (HFE) gene, with osteoarthritis.  Here, we 
will discuss our main findings and their relevance, followed by future prospects in the field of 
research in osteoarthritis and hemochromatosis. 
5.1.1. Osteoarthritis definitions: Renew classifications  
The first part of Chapter 2 describes the definitions and classifications of osteoarthritis in 
brief. For long, epidemiological studies use the Atlas of Standard Radiographs of Arthritis 
developed in 1963.4 It is clear that there is no clear relation between radiographic 
abnormalities and clinical sign and symptoms of osteoarthritis,5 and thus, the definition of 
osteoarthritis needs to develop. The ACR criteria, renewed the definitions of clinical 
osteoarthritis for knee,5 hand6 and hip7 joints for clinicians. A different classification method 
for osteoarthritis, taking into account the knowledge of the underlying molecular basis of 
osteoarthritis in a subset of patients will eventually lead to a more homogenous classification 
of the disease. As yet, however, genetic studies on osteoarthritis apply for too many 
definitions to decide which phenotype classes rely on different genetic etiology. 
 
CHAPTER 5                                                                                                                                                                                      . 
 
 
 
138 
5.1.2. Genetics of osteoarthritis: many studies, few replications 
The second part of Chapter 2 focuses on the genetic epidemiology of osteoarthritis, 
summarizing, first, the evidences on the heritability of osteoarthritis. Heritability estimates of 
osteoarthritis range from 27 up to 65 percent. Heritability has been estimated as 56 percent for 
hand osteoarthritis,8 58 to 65 percent for hip,9,10 and 44 percent for knee,11 joints. The 
heritability estimates among the studies may not be completely comparable due to differences 
in design i.e. population-based versus twin studies, definition of phenotypes i.e. radiographic, 
clinical or pathological, and applied statistical approaches to analyze the data and influences 
of potential confounding factors such as age, gender and body mass index. Indeed one may 
argue true differences among populations may exist due to differences in genetic background, 
and biomechanical stress in these populations. Overall, the fact that osteoarthritis is a heritable 
condition is beyond any doubt. 
The finding that osteoarthritis is a heritable condition raises the question of where 
osteoarthritis susceptibility genes are located across the genome. As reviewed in Chapter 2.1, 
multiple genomic regions have been linked to osteoarthritis on almost all chromosomes i.e. 
chromosomes 1, 2, 3, 4, 7, 9,11, 13, 15, 16, 19, 20 and X.13-31 As it is clear, while some of the 
identified loci implicated in osteoarthritis appear to be involved in several joint sites, others 
may express a site-specific phenotype. 
One of the major concerns in genetic studies that have been conducted in the field of 
osteoarthritis is the reproducibility. There is hardly any replication among the studies, with 
the exception of chromosome 2. No replication may of course be due to both false positive 
and false negative findings. In the field of osteoarthritis, this may be reasonably expected as 
repeated sub-cohort analyses were performed on the same participants of the main cohorts to 
a great extent. The lack of replication may be explained by phenotypic diversity due to 
clinical-based classification of patients or it may partly represent, genetic diversity of 
osteoarthritis. Lack of replication may also arise from differences between the design of 
studies including a priory mapping strategies i.e. map-based or sequence-based designs,32,33 
choice of type and number of SNPs or markers in terms of variant frequencies and effect 
size,33 utilization of appropriate technologies for genotyping.32 Differences in applied 
statistical methods and inferences at the level of statistical significance,32 and levels of 
multiple comparisons,32 are other points to be considered when dealing with lack of 
replication in linkage studies. 
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The other issue to be considered when comparing the results of linkage or association 
studies is the population structure. Lack of replication may originate from differences in the 
degree to which population differ in terms of genetic susceptibility and linkage disequilibrium 
structure,33 the extend and structure of the pedigree and population,33 and population 
stratification.34 Another point that needs to be addressed is at what distance do we reject the 
hypothesis that two location estimates in a genomic region represent the same gene? It is 
suggested that even with relatively large numbers of multiplex families, chance variation in 
the location estimate is substantial and may be a function of magnitude of the estimated LOD 
score.35  
5.1.3. The COL9A1 gene and hip osteoarthritis: A replication study  
Chapter 3.1 describes our investigations on the relationship between the two 12B1 and 8B2 
COL9A1 markers and radiographic osteoarthritis at hand, hip, knee and spinal joints in the 
general population. We used two different designs; in a sibling-pairs study, we found that 
concordant affected sibling-pairs with radiographic osteoarthritis at the hip shared 
significantly more often alleles at the maker 8B2 in the COL9A1 gene than expected. No 
linkage of COL9A1 509-12B1 or 509-8B2 to radiographic osteoarthritis at other joints was 
found. To confirm and extend the findings to an out-bred population, we found the frequency 
of 8B2 alleles were significantly different between persons with radiographic osteoarthritis 
and controls within the population-based Rotterdam Study. 
In our study, several issues are of important consideration. At the design step of a 
candidate gene approach, a key point to success is the selection of candidates. There is 
evidence supporting a role for the COL9A1 gene, mapped to 6q12-13, in osteoarthritis. The 
evidence can be summarized as (a) the role of COL9A1 polypeptide, as a structural protein, in 
the stability of joint cartilage, (b) functional studies that showed that synthesis of alpha1(IX) 
polypeptides to be essential for the assembly of heterotrimeric collagen IX molecules,36 (c) 
transgenic mice that express a non-functional protein as well as knock-out mice that develop 
generalized,37 or early onset knee,38 osteoarthritis, and in human, (d) the COL9A1 mutation 
that was identified as one of the causes of multiple epiphyseal dystrophy, a phenotype 
associated with osteoarthritis,39 (e) the COL9A1 509-8B2 marker that has been linked to hip 
osteoarthritis in women in an affected sibling-pairs study of female patients with severe form 
of osteoarthritis in the UK cohort.40 The other issue to be considered when interpreting our 
findings is the characteristics of the candidate markers genotyped. First, the 12B1 and 8B2 
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COL9A1 markers are short tandem repeat polymorphism leading to 10 and 12 different 
variants of the COL9A1 gene, respectively. In contrast to a linkage study, the relation in an 
association study, can be easily missed since the repeat markers used have a large number of 
rare alleles. In the present study, the polymorphic nature of the studied markers resulted in 
multiple strata of cases and controls, thus, demolishing the power of the association study. 
The other point is that although, we hypothesize that the COL9A1 locus contributes to 
osteoarthritis susceptibility, the 8B2 marker is not likely causally related to radiographic 
osteoarthritis. Thus, 8B2 may be in linkage disequilibrium with an osteoarthritis susceptibility 
mutation within or close to the COL9A1 locus. The association was not specific for a single 
allele. This could be explained if a casual mutation resides on different haplotypes in linkage 
disequilibrium with 8B2 alleles. The last point to be mentioned is that in our sibling-pairs 
data, there was no evidence for a role of COL9A1 in other forms of osteoarthritis. Further 
studies are necessary to identify the underlying mutation in COL9A1 or within a nearby 
osteoarthritis susceptibility locus. 
5.1.4. The HFE gene and arthropathy 
Chapter 3.2 describes the relationship between the C282Y and H63D mutations in the HFE 
gene and arthropathy. In a random cohort drawn from the population-based Rotterdam Study, 
overall, we found that subjects homozygous for H63D compared to non-carriers had 
significantly more often arthralgia, oligoarthralgia, and Heberden’s nodes. When the data was 
stratified by age, in persons aged 65 years or younger, H63D homozygotes had significantly 
more often polyarthralgia, chondrocalcinosis at hip or knee joints, increased number of hand 
joints with radiographic osteoarthritis, and Heberden’s nodes. We found no relation of 
arthralgia or joint pathology to C282Y. We conclude that the H63D mutation may explain at 
least in part the prevalence of arthralgia, chondrocalcinosis, and hand osteoarthritis in the 
general population. 
When discussing our findings, several points need to be addressed. The first point is 
why we did not find any relation to the C282Y mutation. This is important as C282Y is the 
main mutation causing hemochromatosis and has been associated with the highest levels of 
serum iron levels in patients with hemochromatosis,41 and in the general population.42,43 Lack 
of a significant association between osteoarthritis and C282Y may be due to the low number 
of subjects homozygous for this mutation due to other mortality. This may not be true, as a 
large population-based study,44,45 also did not find a significant difference in the prevalence of 
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pain between C282Y homozygosity and controls. Two studies reported a small but significant 
association between C282Y and chondrocalcinosis,46 and hand osteoarthritis at age more than 
65 years.47 The earlier finding were only based on two individuals, and the frequency of 
chondrocalcinosis in the control group was unknown, and the base population for cases (UK) 
and controls (Australia) was different.48 In the latter study, also, the prevalence of 
radiographic hand osteoarthritis is unknown in the control group. Further, the authors did not 
discuss the lower frequency of H63D homozygotes in elder subjects with osteoarthritis which 
preclude any assessment on their potential effect on osteoarthritis.48 The lower frequency of 
H63D homozygotes can be a result of selective survival at young age. Overall, based on our 
findings and given the low prevalence of C282Y homozygosity, we conclude that C282Y is 
not an important factor for osteoarthritis in the general population. 
Our findings support the H63D mutation as one of the candidate mutations implicated 
in osteoarthritis in the general population. We found a strong and consistent association to 
H63D homozygotes not only in arthralgia, a subjective outcome, but also, in the underlying 
pathology including chondrocalcinosis, radiographic osteoarthritis at hands, and Heberden’s 
nodes. Based on our findings, H63D homozygosity may explain 4 percent of the occurrence 
of pain, 13 percent of chondrocalcinosis, and 6 percent of hand nodal osteoarthritis in the 
general population aged 65 years or younger. Previous studies did not investigate this 
mutation in details.48 Both C282Y and H63D are associated to significant iron overload in the 
Rotterdam study. In brief, C282Y homozygotes and heterozygotes, compared to non-carriers, 
had significantly higher levels of serum iron (p<0.001), ferritin (p<0.01), and transferrin 
saturation (p<0.001). Similarly we found that H63D homozygotes, compared to non-carriers, 
had significantly higher levels of serum iron (p<0.001), ferritin (p<0.03) and transferrin 
saturation (p<0.001). As discussed in Chapter 3.2, however, there is strong evidence 
suggesting that iron overload alone may not explain hemochromatosis-associated arthropathy. 
In fact, in our population and in those of others there was a poor correlation between serum 
iron indices and arthropathy in hemochromatosis49-51 suggesting the involvement of an 
alternative mechanism i.e. an inflammatory components, in H63D associated arthropathy. 
5.1.5. The HFE gene, osteoarthritis and mortality: A new role for inflammation 
The investigation of why we did find a strong and consistent association to H63D 
homozygosity in persons aged 65 years and younger and why we did find no relation in 
persons aged 65 years or over, led us to another striking finding (Chapter 3.3). Subjects 
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homozygous for the H63D mutation with pain had a significantly earlier mortality than non-
carriers without pain in persons aged 65 years or younger (Chapter 3.2). We hypothesized 
that an underlying inflammatory pathway may explain the relation between H63D 
homozygosity, joint pain, and mortality. In particular, Heberden’s nodes, a known hereditary 
condition,52 has an inflammatory component. We tested this hypothesis in a population-based 
Rotterdam Study where the participants have been followed up to 14 years. We found that 
subjects homozygous for H63D and Heberden’s nodes died earlier most likely due to stroke 
than wild-type homozygotes without Heberden’s nodes (Chapter 3.3). This observation led 
us to test the relation between H63D homozygosity and levels of serum C-reactive protein 
(CRP). We found that H63D homozygotes with Heberden’s nodes had significantly higher 
levels of serum CRP compared to wild type homozygotes with or without Heberden’s nodes. 
Our epidemiological investigations suggest that H63D homozygosity has a joint effect with 
Heberden’s nodes coincides with a higher inflammatory status, and to an increased mortality 
due to vascular pathology. 
Some points are of consideration. First, our findings remain to be confirmed by others. 
Second in depth experiments are required to unravel the detailed mechanism by which H63D 
lead to a higher inflammatory status. The finding of such studies will prove or reject our 
hypothesis. 
5.1.6. The HFE gene, and longevity: Bilirubin opposes inflammation 
The other point of interest in our study population was the course of the C282Y mutation. In 
our cohort, subjects heterozygous or homozygous for the C282Y mutation had a significant 
iron overload.53 These subjects did not have a clinical diagnosis of hemochromatosis, neither 
did diabetes mellitus,54 arthropathy (Chapter 3.2), or liver pathology. These observations are 
in line with previous reports.44,55,56 Further, similar to the findings of others,57 survival 
analyses revealed none of C282Y homozygotes died during a follow-up of 15 years and 
indeed C282Y carriers did not show a shorter life span in this elderly cohort. The low 
penetrance of C282Y mutation, while the carriers have a higher iron status, encourages 
investigators, as well as us, to hypothesize the presence of modifiers, which counteract the 
adverse effects of iron overload. As discussed in Chapter 3.4 serum bilirubin, a strong 
antioxidant, was found at increased levels in patients with hereditary hemochromatosis.58 We 
hypothesized that the increased serum bilirubin levels may play a protective role against 
oxidative stress induced by iron overload in carriers of mutations in HFE.59,60 
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We found that serum bilirubin levels were significantly correlated with serum ferritin 
iron and transferrin saturation, and carriers of C282Y and H63D had a significantly higher 
levels of serum bilirubin. Further, high serum bilirubin was associated with a 2.8 fold 
reduction in mortality in H63D homozygotes and two folds reduction in mortality in C282Y 
heterozygotes. We suggested that the high levels of bilirubin may counteract the adverse 
effects of oxidative stress induced by iron overload, which may explain in part the reduced 
penetrance of the HFE mutations. Hemeoxygenase pathway, a strong anti-inflammatory and 
antioxidant mechanism in organism,59,60 may explain the observed associations, although this 
remains to be tested in epidemiological and experimental studies. 
5.1.7. Heritability of serum iron indices in a Dutch isolate; First step to identify 
genes in iron metabolism 
The observed low penetrance or the genotype phenotype correlation in hemochromatosis 
raised the question to what extend the HFE mutations can explain the variation in the levels of 
iron in the general population. We as well as others have found that only 5 percent of body 
iron levels can be explained by the HFE mutations.53,61 The remaining proportion is explained 
by other genetic and environmental factors, or gene-environmental interactions that still 
remains to be identified. As a first step towards identifying genes involved in iron 
metabolism, we investigated the heritability of serum iron indices, including iron, ferritin, and 
transferrin saturation (Chapter 4). In a Dutch isolate, we found a heritability estimate of 0.17 
for iron, 0.24 for serum transferrin saturation, and 0.26 for ferritin. We conclude that a modest 
proportion of the variance of iron and ferritin can be explained by heredity, independent of 
sex, age and environmental effects. Our results demonstrate the influence of both genetic and 
environmental factors on iron levels. The next question remains to answer is to what extent 
the heritability estimates can be explained by known genes in the studied genetic isolate. 
5.2. Future Perspectives 
There are several challenges in the head of both hemochromatosis and osteoarthritis. Chapter 
2.1 discusses classification of osteoarthritis. In osteoarthritis, like other complex disorders, 
clinical definition of disease obscures multiple mechanistically distinct subtypes. New genes 
revealed previously unsuspected biochemical pathways that could explain the pathogenesis. 
This will help to a predictive diagnosis and introduce an appropriate individualized therapy. 
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Future research will show to how many sub-phenotypes do really exist; and to what extent the 
subgroups of osteoarthritis differ in causal pathway, risk of developing disabilities, prognosis 
and response to treatment.62,63 
It is clear that few of the genes found to be associated with osteoarthritis mapped to 
the known linkage regions (Chapter 2.1). This indicates that most of the causal mutations 
responsible for the found genomic intervals remain unknown. The first challenge in the future 
will be to identify those yet unknown genes. This can be addressed by a careful sub-
phenotyping (different sub-phenotypes should not lumped together), analyzing the genes 
involved in the same pathway or in the same regulatory network, careful evaluation or 
interpretation of the findings from the association or linkage studies, development of 
internationally collaborative consortium, which share the databases and genomic 
information.62-68 
The other challenge in front of osteoarthritis and hemochromatosis is uncovering the 
pathways involved in the disease pathogenesis. It is clear within the large well-defined 
cohorts such as the Rotterdam Study, the Framingham Study, and the UK Sibling-pairs 
cohort, multiple genes or genomic regions were associated or linked to osteoarthritis. In 
hemochromatosis also multiple genes are involved in the pathogenesis. And still for both 
diseases many genes will yet come. 
Elucidating the relationship between genotype and phenotype is one of the most 
challenging and important tasks of the future research in osteoarthritis as well as 
hemochromatosis. The question that also needs to be answered is how genes interact with 
each other and environmental factors. The large national epidemiological population-based 
follow up studies with well characterized participating individuals for their diseases, 
biomarkers and genetic variations are necessary to demonstrate multiple effects of a single 
genotype, the detailed relationship between genetic markers and clinical phenotypes, the 
course of the disease over time, and the final outcome of gene-gene, and gene-environmental 
interactions.  
The next challenge, for the area of osteoarthritis, is to translate the genomic 
information to clinical practice. In spite of recent advances in osteoarthritis, current treatment 
in osteoarthritis is palliative, focusing on analgesics and surgical interventions and the genetic 
counseling plays no more than nothing in the disease prediction and prevention. Development 
of the genome variations involved in osteoarthritis or hemochromatosis, raises the question 
whether screening based on such a genomic portrait can be used to predict or to prevent the 
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disease, and to identify drug targets and predict therapeutic response. This is a major 
challenge for many complex disorders in the coming decade.62,65,69  
For hemochromatosis, this prospect is far more advanced than osteoarthritis, as the 
causal mutations have already been identified, molecular-based disease sub-phenotyping is 
possible, the effective therapeutic treatment is available, genotype-phenotype correlation has 
been widely investigated and early diagnosis and intervention before organ damage improves 
prognosis. Our data (Chapter 3.2) suggest that one of the indications for genetic testing is 
hand osteoarthritis which has already been included as one of the criteria for 
hemochromatosis.64 Hemochromatosis is one of the diseases that fulfill the WHO guidelines 
for screening.64 Still the challenge forward is to characterize the at risk population for genetic 
screening and prevention effectiveness of population-screening.64,70 Although simple and 
effective biochemical tests for iron overload are available, genetic testing may be a cost 
effective alternative. In 1996, Feder and colleagues showed that bout 85 percent of 
hemochromatosis patients are carriers for the common C282Y and H63D mutation.41 From 
this, one may predict that screening for the C282Y mutation should ascertain most patients 
reliably. This encouraged investigators and public health experts to initiate genetic screening 
programs in young population,71 blood donors,72 or children of hemochromatosis 
homozygotes.44,73,74 However, these initiatives were soon hampered by the findings of a poor 
correlation between the HFE C282Y genotypes and clinical hemochromatosis.75,76 If genetic 
screening is not informative for hereditary hemochromatosis, there remains little hope for the 
usefulness of genetic screening for other disorders. Perhaps the most important lesson to be 
learned is that predictions from selected families with hereditary forms of diseases such as 
hemochromatosis and other diseases cannot be translated to the general population without 
thorough research in large population samples. Although not impossible, it will be a tall order 
to study major genes such as HFE in the general population with sufficient statistical power. 
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SUMMARY 
Chapter 2.1 provides a review on the genetic epidemiology of osteoarthritis. Twin and family 
studies showed that heritability estimate varies between 27 to 60 percent, depending on the 
inclusion criteria for ascertainment of subject i.e. clinical, radiographic or pathologic 
phenotype and the affected joint locations. Using positional cloning multiple genomic region 
have been linked to osteoarthritis. These regions barely overlap. Few regions have been 
replicated in different studies. Candidate gene studies have associated multiple genes, most of 
them do not map to the known linkage regions, to osteoarthritis. This leaves most of the genes 
responsible for linked regions unidentified. 
Chapter 2.2 reviews the genetic epidemiological aspects of hereditary hemochromatosis. 
Multiple genes have been identified for different clinically distinct phenotypes of 
hemochromatosis. Type I hemochromatosis, is the most common form of the disease, which 
is explained by mutations in the HFE gene. The discovery of the common C282Y (carriers 
rate 13 percent and associated to high iron levels in Caucasians) and H63D (carrier rate 23 
percent worldwide and associated to a modest increase in iron levels) mutations in the HFE 
gene provides a potential mutation testing to prevent an adult-onset disease phenotype.  
Chapter 3.1 presents the results of our linkage and association study on the relationship 
between the COL9A1 gene and osteoarthritis at hand, knee, hip and spinal joints. Within the 
Rotterdam Study, a population-based study of 7983 subjects aged 55 years or over, we used 
two different designs. We found that affected sibling pairs with hip radiographic osteoarthritis 
shared significantly more often alleles IBD at the 8B2 and 12B1 markers than expected. No 
excess sharing was observed for radiographic osteoarthritis at other joint sites. When 
comparing the allele frequency of 8B2 and 12B1 in cases and controls, the frequency of 8B2 
alleles in cases differed significantly from those of controls. Our data suggests that 
susceptibility for hip osteoarthritis is conferred within or close to the COL9A1 gene in linkage 
disequilibrium with the COL9A1 509-8B2 marker.  
Chapter 3.2 discusses our findings on the relationship between the HFE gene and 
osteoarthritis. We investigated the relation between the HFE C282Y and H63D mutations 
with arthralgia and joint pathology in the population-based Rotterdam Study. Overall, there 
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was a significantly higher frequency of arthralgia, oligoarthralgia and Heberden’s nodes in 
those homozygous for H63D compared to non-carriers. In persons aged 65 years or younger, 
H63D homozygotes had significantly more often polyarthralgia, chondrocalcinosis at hip or 
knee joints, increased number of hand joints with osteophytes space narrowing, radiographic 
osteoarthritis, and Heberden’s nodes. We found no relation of arthralgia or joint pathology to 
C282Y, but compound heterozygotes had a significantly higher frequency of arthralgia, 
chondrocalcinosis at hip, and increased number of osteophytes at knee joints at late age (65 
years or over). We conclude that the H63D mutation may explain at least in part the 
prevalence of arthralgia, chondrocalcinosis, and hand osteoarthritis in the general population. 
Chapter 3.3 reports our findings on the relationship between the H63D mutation, Heberden’s 
nodes and mortality. Our study on the relation between the H63D mutation, Heberden’s 
nodes, an inflammatory related local form of osteoarthritis, and their joint effect on overall 
and cause-specific mortality. Within the Rotterdam Study, we found no relation to HFE H63D 
genotypes in mortality. Presence of Heberden’s nodes was significantly related to a modest 
increase in mortality. Persons homozygous for the H63D mutation with Heberden’s nodes had 
a substantial increase in risk of mortality compared to subjects homozygous for the wild type 
allele without Heberden’s nodes. This increase in mortality was explained by an increase risk 
of mortality due to stroke. Persons homozygous for H63D with Heberden’s nodes are 
characterized by increased levels of C-reactive protein (CRP) in serum (p<0.001). Increased 
levels of serum CRP were not found in those with Heberden’s nodes who were not 
homozygous for the H63D mutation. The increased inflammatory state in carriers may explain 
in part the increased mortality due to stroke. Our study suggests that inflammation may 
explain the increased risk of mortality of H63D homozygotes with Heberden’s nodes. 
Chapter 3.4 explains our findings on the relationship between HFE mutations and serum 
bilirubin. Within the Rotterdam Study, overall, serum bilirubin levels were significantly 
correlated with serum iron (p<0.001), transferrin saturation (p<0.001) and serum ferritin 
(p=0.03). Carriers of the HFE mutations had higher level of serum bilirubin compared to the 
wild type homozygotes in particular H63D homozygotes and C282Y heterozygotes. The high 
serum bilirubin was associated to a 2.8 fold reduction in mortality in H63D homozygotes and 
a 2.2 fold reduction in mortality in C282Y heterozygotes. Taken together, our data suggests 
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that the high levels of bilirubin may counteract the adverse effects of oxidative stress induced 
by iron overload, which may explain in part the reduced penetrance of the HFE mutations. 
Chapter 4.1 describes the results of our study to estimate the magnitude of genetic influences 
on iron and ferritin levels in relatives from a recent genetic isolate in the Netherlands. The 
participants analyzed in this study included 90 nuclear families with a total of 988 subjects. 
The proportion of the residual phenotypic variance due to additive genetic effects i.e. 
heritability estimates were approximately 0.17 (p<0.0001) for iron, 0.24 for transferrin 
saturation (p<0.001) and 0.26 (p<0.0001) for ferritin, while adjusting for sex, age and levels 
of serum albumin. A substantial proportion of the variance of iron, transferrin saturation, and 
ferritin can be explained by heredity, independent of sex, age, and environmental effects. Our 
results demonstrate the influence of both genetic and environmental factors on iron levels. 
Identification of genes influencing iron and ferritin levels using a QTL approach is feasible. 
Chapter 5 provides a general discussion of the studies presented in this thesis in context of 
current knowledge and ongoing research in the field of genetic epidemiology of osteoarthritis 
and hemochromatosis. 
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SAMENVATTING 
Hoofdstuk 2.1 bevat een overzicht van de genetische epidemiologie van osteoarthritis. 
Tweeling studies en familiestudies toonden dat de bijdrage van de erfelijkheid varieert tussen 
27 en 60 procent, afhankelijk van de inclusie criteria op grond van het klinisch, radiologisch 
of pathologisch fenotype en de ligging van de aangedane gewrichten. Met positional cloning 
technieken zijn meerdere gebieden op het genoom gelinkt met osteoarthritis. Deze gebieden 
vertonen nauwelijks overlap. Weinig gebieden zijn gerepliceerd in te verschillende studies. 
De kandidaatgen studies hebben associaties van osteoarthritis met meerdere genen laten zien. 
De ligging van de meeste genen correspondeert echter niet met de bekende chromosomale 
gebieden die koppeling vertonen. De meeste genen in gebieden die koppeling tonen zijn dan 
ook nog niet geïdentificeerd. 
Hoofdstuk 2.2 geeft een overzicht van de genetisch epidemiologische aspecten van erfelijke 
hemochromatose. Meerdere genen zijn geïdentificeerd voor verschillende klinisch te 
onderscheiden kenmerken (fenotypen) van hemochromatose. Primaire hemochromatose, de 
meest voorkomende vorm van de ziekte, wordt verklaard door aanwezigheid van mutaties in 
het HFE-gen. De ontdekking van de algemene C282Y-mutatie (dragerschap frequentie 
bedraagt 13 procent en er in een associatie met hoge serum ijzer spiegels bij personen van 
Noord-Europese afkomst) en de H63D mutatie (wereldwijde dragerschap frequentie 23 
procent met matig verhoogde ijzer spiegels) in het HFE-gen, maakt potentieel testen op 
mutaties mogelijk om de op volwassen leeftijd optredende vorm van de ziekte te voorkomen. 
Hoofdstuk 3.1 toont de resultaten van onze koppeling- en associatie studie over het verband 
tussen het COL9A1 gen en osteoarthritis van de hand, knie, heup en wervelkolom. Binnen de 
ERGO-studie, een populatie studie bij 7983 personen van 55 jaar of ouder, gebruikten wij 
twee verschillende ontwerpen. Wij vonden dat aangedane sibling paren (broer-broer, zus-zus 
of broer-zus paren) met radiologisch gediagnosticeerde osteoarthritis van de heup significant 
vaker dan verwacht allelen deelden (Identical By Descent) op de DNA markers 8B2 en 12B1. 
Er werd geen bovenmatig delen van beide allelen voor een marker waargenomen bij 
radiologisch gediagnosticeerde osteoarthritis van andere gewrichten. Een vergelijking van de 
allel frequenties van 8B2 en 12B1 in patiënten en controles toonde een significant verschil in 
de frequentie van allelen 8B2 tussen patiënten en controles. Onze gegevens suggereren dat de 
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genetische gevoeligheid voor osteoarthritis van de heup binnen of dicht bij het gen COL9A1 
linkage disequilibrium is met de marker COL9A1 509-8B2. 
In hoofdstuk 3.2 bespreken wij onze bevindingen over het verband tussen het gen HFE en 
osteoarthritis. Wij onderzochten de relatie van HFE C282Y en H63D mutaties met artralgie 
en gewricht pathologie in de ERGO-studie. Als totaal werd een significant hogere frequentie 
van artralgie, oligoartralgie en Heberden nodules gevonden bij homozygoten voor H63D dan 
bij niet-dragers. In personen van 65 jaar of jonger hadden H63D homozygoten significant 
vaker polyartralgie, chondrocalcinosis bij/van heup of knie gewrichten, een verhoogd aantal 
handgewrichten met osteophyten, radiologisch gediagnosticeerde osteoarthritis, en Heberden 
nodules. Wij vonden geen relatie van artralgie of gewricht pathologie met C282Y, maar 
samenstelde heterozygoten hadden een significant hogere frequentie van artralgie, 
chondrocalcinosis van de heup, en verhoogd aantal osteophyten bij knie gewrichten op latere 
leeftijd (65 jaar of ouder). Wij concluderen dat de H63D mutatie op zijn minst voor een deel 
de prevalentie van artralgie, chondrocalcinosis en osteoarthritis van de hand in de algemene 
bevolking kan verklaren. 
Hoofdstuk 3.3 vermeldt onze bevindingen over het verband tussen de H63D mutatie, de 
nodules van Heberden en morbiditeit. Onze studie onderzoekt de relatie tussen de H63D 
mutatie, de nodules van Heberden, een inflammatoire verwante lokale vorm van osteoartritis, 
en hun gezamenlijk effect op algemene en oorzaak-specifieke mortaliteit. Binnen de ERGO-
studie vonden wij geen relatie met HFE H63D genotypen en mortaliteit. De aanwezigheid van 
de nodules van Heberden was significant geassocieerd met een bescheiden verhoging van 
mortaliteit. Voor de H63D mutatie homozygote individuen met de nodules van Heberden 
hadden een aanzienlijke toename van het risico op mortaliteit in vergelijking met voor het 
wild-type homozygote personen zonder nodules van Heberden. Deze toename van mortaliteit 
werd verklaard door een verhoogd risico op mortaliteit ten gevolge van een beroerte. Voor de 
H63D mutatie homozygote individuen met de nodules van Heberden worden gekenmerkt 
door verhoogde serum spiegels c-reactieve proteïne (CRP; p<0,001). Verhoogde CRP serum 
spiegels werden niet gevonden in individuen met de nodules van Heberden die niet 
homozygoot waren voor de H63D mutatie. De verhoogde staat van ontsteking in dragers van 
deze mutatie kan voor een deel de verhoogde mortaliteit ten gevolge van een beroerte 
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verklaren. Onze studie doet vermoeden dat ontsteking het verhoogde risico op mortaliteit van 
H63D homozygoten met de nodules van Heberden kan verklaren. 
Hoofdstuk 3.4 biedt een verklaring voor onze bevindingen over de relatie tussen HFE 
mutaties en serum bilirubine. Binnen de ERGO-studie als totaal waren serum bilirubine 
spiegels significant gecorreleerd met serum- ferritine (p=0,03), ijzer (p<0,001), en 
transferrine-saturatie (p<0,001). Dragers van de HFE mutaties bezaten hogere serum 
bilirubine spiegels dan the wild-type homozygoten in het bijzonder H63D homozygoten en 
C282Y heterozygoten. Hoog serum bilirubine was geassocieerd met een 2,8-voudige reductie 
in mortaliteit in H63D homozygoten en met een 2,2-voudige reductie in C282Y 
heterozygoten. Samenvattend suggereren onze gegevens dat de hoge bilirubine spiegels de 
nadelige effecten kunnen tegenwerken van door ijzer overbelasting geïnduceerde oxidatieve 
stress, wat voor een deel de gereduceerde penetrantie van de HFE mutaties kan verklaren. 
Hoofdstuk 4.1 beschrijft de resultaten van onze studie die tot doel heeft de grootte in te 
schatten van genetische invloeden op ijzer en ferritine spiegels in verwanten uit een recent 
genetisch isolaat in Nederland. Tot de deelnemers aan deze studie behoorden 90 kernfamilies 
van in totaal 998 personen. Het deel van de residuele fenotypische variantie ten gevolge van 
additief genetische invloeden d.i. bijdragen van de erfelijkheid waren circa 0,26 voor ferritine 
(p<0,0001), 0,17 voor ijzer (p<0,0001) en  0,24 voor transferrine-saturatie (p<0,001) onder 
aanpassing voor geslacht, leeftijd en serum albumine spiegels. Een aanzienlijk deel van de 
variatie van ijzer, transferrine-saturatie en ferritine kan worden verklaard door erfelijkheid, 
onafhankelijk van geslacht, leeftijd en omgevingsinvloeden. Onze resultaten tonen de invloed 
van zowel genetische als omgevingsfactoren op ijzer spiegels aan. Identificatie van genen die 
de ijzer en ferritine spiegels beïnvloeden met een QTL aanpak is haalbaar. 
Hoofdstuk 5 geeft een algemene discussie van de studies die in dit proefschrift worden 
gepresenteerd in samenhang met hedendaagse kennis en lopend onderzoek op het gebied van 
de genetische epidemiologie van osteoarthritis en hemochromatose. 
 

 
 
 
 
 
EPILOG 

 165
A PERSONAL WORD OF THANKS 
It is of my sincere grateful to thank these people who without them this thesis would not 
simply be possible. 
I sincerely express my greatest gratitude to my promoter prof.dr.ir. Cornelia M. van 
Duijn for her excellent professional insights, brilliant thoughts, knowledgably guidance and 
wonderful patience both in my scientific and personal life during the last few years. Dear 
Cornelia, I deeply thank you for helping me to develop new knowledge, which resembles a 
new scientific life and I must not forget to thank you particularly for helping me in 
understanding again what I have forgotten. I thank wholeheartedly my other promoter, 
prof.dr. Petronella E. Slagboom for her vital part in developing the work described in the 
present thesis. Dear Eline, you generously continued to provide your valuable comments even 
when other things were making enormous demands on your time and attention. Our scientific 
discussions have even been extended to your Christmas holidays. I thank you also for your 
constant encouragement and good humor that keeps my hope high and spirit strong in very 
difficult moments. 
I deeply thank the member of my reading committee from Erasmus MC, prof.dr. 
Johanne M.W. Hazes, prof.dr. Ben A. Oostra, prof. Paul M. Wilson, for agreeing to be on my 
doctoral committee and for their highly appreciated critical comments that provided valuable 
insights on manuscripts and the thesis. I am grateful to prof.dr. Theo Stijnen (EMCR) and dr. 
Dorin W. Swinkels (UMCN) for being in the plenary committee and to Theo for his 
wonderful courses in biostatistics and his valuable statistical advises and to Dorine for her 
comments on “heritability paper” and for her collaboration on phenotyping the ERE 
population for serum iron indices. 
My deep gratitude goes to prof.dr. Cisca Wijmenga (UMCU), dr. Bobby P.C. 
Koeleman (UMCU) and dr. Bart O. Broep (LUMC), without their unconditional support it 
was not possible to finalize this thesis. My gratitude goes to prof.dr. Amado S. Peña (VUMC), 
for giving me the opportunity to join his research group at Immunogenetic laboratory during 
my DSc program. Dear Salvador and Sandra, I thank you for your support, friendship and 
open personality in the time that my family and I needed the most. I would like to express my 
deepest thank to my mentor prof.dr. Reza Malekzadeh (TUMC) chairman of Digestive 
Diseases Research Center, with whom I have started doing research since 1993, for his highly 
appreciated supports during my work at DDRC and my MSc. program in the year 2000 
 166
A special thank to my copromoter dr. Omer T. Njajou for his comments and critical 
review of my manuscripts, for his many advises on preparing papers and presentations. Dear 
Omer, we started working together when you were in the last year of your PhD program. 
Soon, we celebrated your promotion, after all difficulties that you had been led through. Since 
then you became my copromoter. This thesis presents our second major effort in the era of 
hemochromatosis. I thank you for all you have taught me and I wish you the best in your new 
courier. 
From the Department of Epidemiology & Biostatistics, Erasmus MC, I wish to thank 
prof.dr. Albert Hofman for his brilliant comments and thoughtful advises on my papers, for 
teaching us the fundamental of epidemiology, for giving me, among others, the opportunity of 
assisting in his courses at Erasmus Summer Programs, and for his continuous encouragement, 
prof.dr. Monique M.B. Breteler, for all I have learned from her about neuro-epidemiology in 
different courses, and for her critical comments and advises on my paper, dr. Jacqueline C.M. 
Witteman for her excellent consultancy on cardiovascular research as well as about the 
methods in epidemiology, and prof.dr. Bruno H.C. Stricker for his valuable insight and 
gratefully appreciated collaboration on “the liver project” in the Rotterdam Study. I extend 
my deep gratitude to prof.dr. Huibert A.P. Pols, department of internal medicine (EMCR) for 
his thoughtful clinical as well as epidemiological advises on my papers. I must here remember 
dr. Lodewijk Sandkuijl for his excellent courses on genetic epidemiology and linkage 
analysis. 
I thank dr. Esther Croes for her kind to honor me to be my paranymf, for her highly 
acknowledged comments on the thesis, for her enormous brilliant quality of efforts on the 
ERF Study and for her kind help and advise. I thank also dr. Fernando Rivadeneira Ramirez, 
my dear friend, who also honored me to be my paranymf and for many thoughtful scientific 
discussions that we have enjoyed together since we started MSc program. 
It is my great pleasure to thank dr. Jeanine J. Houwing-Duistermaat (LUMC) for the 
help with data analysis and interpreting the results who always has the right answers to my 
statistical questions. I thank dr. Ingrid Meulenbelt (LUMC) for her generous help and greatly 
acknowledged remarks on “COL9A1 and osteoarthritis” paper. I appreciate the great efforts 
of dr. Yurii S. Aulchenko for his statistical guidance in analyzing the ERF data. I am deeply 
grateful to dr. Bart Crusius (VUMC) for his support during my DSc program and in particular 
for his kind help in translating the summary of the thesis to Dutch. I extend my thank to dr. 
Sita M.A. Bierma-Zeinstra (EMCR) for her very appreciated guidence in the epidemiology of 
osteoarthritis on “HFE and screening” paper. 
 167
I had also bright MSc students who worked very extraordinary on several papers. I 
would like to thank dr. M.R. Millán (Mexico) and dr. F. Elsheikh (Sudan) for their enormous 
motivation and hard work to analyze data and prepare the manuscripts. In particular, I thank 
my medical students Ms. G.L.M. Chong and Mr. J.G.P. Reijnders who have done more good 
than they know for data collection, management and data analysis followed by well-timed 
appreciative drafting of the manuscripts. Here, I must remember the Netherlands Institute for 
Health Sciences, which provides a unique scientifically interactive environment for students, 
tutors and supervisors. I will like to thank all staff members of the NIHES for helping me 
while I was doing my MSc and DSc programs: Natascha, Soja, Saskia, Lenie, Annet and 
Koos. 
This thesis was not possible without enormous collaborative efforts of many people 
for phenotyping thousands of radiographs of joints for osteoarthritis and genotyping the 
participants for the studied candidate genes. From the department of General Medicine, 
Erasmus MC, I sincerely thank dr. S. Dehageen for providing me phenotypic data on hand 
osteoarthritis and her great contribution to our joint paper. I thank also dr. M. Rijemen, for 
providing me phenotypic data on radiographic hip and knee osteoarthritis. 
I greatly acknowledge the many people contributed to immense laboratory 
measurements that have been used throughout the thesis. I thank Jeannette, Wilma, Tessa, 
Bianca, Ruud, Marijke, and Guido for HFE genotyping of the participants in the Rotterdam 
Study. I thank Aaron Issac for his great efforts in typing the participants in the ERF Study for 
HFE variants. I appreciate the great efforts of Siem Klaver (UMCN) for measurements the 
levels of serum iron indices in the ERF population. I will like to extend my thanks to the 
people who work on the ERF center to collect data and examine the participants: Riet, Els, 
Anke, Dory, Corina, Elly, Margariet, Mira, Tiny, and Lidian and in geneaology team Petra 
and Hilda. 
I wish to thank also dr. Lindsey Criswell (UCSF) for her generosity, scientific advises 
and help in particular for all her motivating efforts on the occasion of “my Borrel party”. And 
many thanks to dr. Cecil Janssen (EMCR) for her constant moral supports and advises both on 
scientific matters and my personal life. Many thanks also to Leon Tester, for his efforts on the 
ERF Study and his encouragements and nice talks. 
Collaborating with several scientific disciplines provided me the opportunity to find 
many respectful friends from many different nationalities, each of them kindly extended their 
hands to help whenever it was needed. I am grateful to all colleagues for their moral support 
and critical commentary, suggestions, and fixes in Genetic Epidemiology Unit, EMCR: Aida, 
 168
Aljandro, Angela, Anna, Carolina, Dominiek, Fakhredin, Ingrid, Jose (Chili), Jouke-Jan, 
Kristel, Liu, Marie-Jose, Marieke, Mark, Mark Sie, Mojgan, Nahid, Norbert, Raschid 
(LUMC), Regie, Sandra, Stefano, Vincenzo and member of lab, Annand, Astrid and Eric. I 
wish to thank Josine in Molecular Epidemiology Section, LUMC for her kind and help. I 
sincerely thank all colleagues for their friendship and support in Complex Genetic Group, 
UMCU: Alienke, Albertien, Bart Jungerious, Bart van de Sluis, Begona, Dalila, Dineke, 
Erica, Harm, Lude, Martin, Marrianna, Sasha, Alfons, and my colleagues in lab: Birgit, Eric, 
Karin, Linda, Ruben, and of course staff members: Harry, Paul, Miriam, Jackie and Judith. I 
wish also to thank my friends and colleagues at the Department of Hematology and 
Immunology, LUMC: Aantje, Anouk, Arno, Gabielle, Laura, Lee, Peterje, and Volkert. 
Yet I should remember the staff of the department of epidemiology for their good 
humor and enormous motivation, which make our daily efforts possible. I wish to thank 
secretarial Marjolijn, Petra and Martie, and computer mans Nano, Marcel, Rene and Eric. 
I must thank my wonderful wife, Leila, for her love and kind, for being incredibly 
understanding, supportive and most of all for her patients who many times got to hear “Sorry, 
I am still writing the papers”. My sweaty Aylar I hope when you get old enough you like 
reading this thesis and you are as proud of your father as he is of you now. Thanks to my 
extended family for their sincere encouragements. Huge thanks to my very dear mother a 
symbol of honesty, kindness and faithfulness. I thank my father for all his love and efforts to 
support his family, my three brothers Parviz, Mahdi and Abolfazl and my the only sister, 
Leila for her enthusiasm. 
 
Finally, in the name and with respect to the One who perfectly demonstrates creative 
excellence.  
 
Behrooz Z Alizadeh,  
12 Feb 2005
 
 
 
 
 169
ABOUT THE AUTHOR 
 
Name   Behrooz Ziad Alizadeh 
Date of birth  01 June 1969 
Place of birth  Tehran, Iran 
Residence  Rotterdam, the Netherlands 
Martial status  Married, one 7 years old daughter 
Academic qualification 
2005: Doctor of Philosophy (PhD) in Genetic Epidemiology, Department of Epidemiology & 
Biostatistics, Erasmus Medical Center, Rotterdam, the Netherlands. 
2002:  Doctor of Science (DSc) in Genetic Epidemiology, The Netherlands Institute for Heath Sciences 
(NIHES), Rotterdam, The Netherlands. 
2001:  Master of Science (MSc) in Genetic Epidemiology, NIHES, Rotterdam, the Netherlands. 
1997:  Doctor in Medicine (MD), Medical School, Tehran University of Medical Sciences, Tehran, 
Iran. 
 Scholarships 
2001: The NIHES, and Immunogenetic Foundation, Free University Medical Center, Amsterdam, the 
            Netherlands for DSc in Genetic Epidemiology. 
2000: Tehran University of Medical Sciences for MSc program in Genetic Epidemiology at NIHES,  
            Rotterdam, the Netherlands. 
Theses 
2005 Thesis for PhD in Genetic Epidemiology. Promoters: Prof.dr. CM Duijn, and Prof.dr. P.E. 
Slagboom. Erasmus Medical Center, Rotterdam, The Netherlands. 
1997 Thesis for Doctor in Medicine (MD) entitled “The Etiology of Chronic Liver Diseases in 
Iran”. Digestive Diseases Research Center (DDRC), Tehran University of Medical 
Sciences. Tehran, Iran; Supervisor: Prof. Dr.  R Malekzadeh. 
Contribution to research development 
1992-2000: Initiation and Establishment (Co-founder) of Digestive Diseases Research Center, 
Tehran University of Medical Sciences, Tehran, Iran. 
 170
List of Publications 
2005 
o Alizadeh BZ, Njajou OT, Bijkerk C, Meulenbelt I, De Wildt SC, Hofman A, Pols HAP, 
Slagboom PE, van Duijn CM. The Gene Encoding for Alpha Domain of Collagen IX 
Proteoglycan (COL9A1) and Hip Osteoarthritis, a Population-based Study. Arthritis Rheum. (In 
press) 
o Alizadeh BZ, Njajou OT, Hazes JMW, Hofman A, Slagboom PE, Pols HAP, van Duijn CM. The 
H63D Mutation in the HFE Gene Predisposes to Arthralgia, Chondrocalcinosis, and 
Osteoarthritis. Arthritis Rheum. (In press) 
o Alizadeh BZ, Chong GLM, Njajou OT, Hazes JMW, Slagboom PE, Hofman A, Pols HAP, van 
Duijn CM. The HFE H63D Mutation, Heberden’s Nodes, and Mortality; the Population-based 
Rotterdam Study. (Submitted) 
o Alizadeh BZ, Njajou OT, van Rijn MJ, Aulchenko Y, van Swieten J, Zillekens C, Klaver S, 
Oostra B, Swinkels D, van Duijn CM. Heritability of Serum Iron, Ferritin, and Transferrin 
saturation in a Genetic Isolate; The Erasmus Rucphen Study. (Submitted) 
o Alizadeh BZ, Dehageen S, Hofman A, Pols HAP, Slagboom PE, van Duijn CM, Hazes JMW. 
Shall patient with MCP osteoarthritis be screened for HFE mutation? (Submitted) 
o Alizadeh BZ, Millán MR, Njajou OT, Hofman A,  Breteler MM, van Duijn CM. 
Hemochromatosis Gene (HFE) Mutations, APOE and Alzheimer’s Disease: A Population-based 
Study. (Submitted) 
o Reijnders JGP, Alizadeh BZ, Njajou OT, Hofman A, Pols HAP, Wilson JHP, Stricker B, van 
Duijn C.M. HFE Mutations and Liver diseases in the general population; Findings from a 
population-based study and meta-analysis. (To be submitted) 
2004 
o Alizadeh BZ, Njajou OT, Houwing-Duistermaat JJ, De Jong G, Vergeer JM, Hofman A, Pols 
HAP, and Van Duijn CM. Does Bilirubin Protect Against Hemochromatosis Gene (HFE) Related 
Mortality? Am J Med Gen 2004; 29:39-43. 
o Croes EA, Alizadeh BZ, Bertoli-Avella AM, Rademaker T, Vergeer-Drop J, Dermaut B, 
Houwing-Duistermaat JJ, Wientjens DP, Hofman A, Van Broeckhoven C, Van Duijn 
CM.Polymorphisms in the prion protein gene and in the doppel gene increase susceptibility for 
Creutzfeldt-Jakob disease. Eur J Hum Genet 2004, 12:389-94 
o Njajou OT, Alizadeh BZ, Van Duijn CM. Is genetic testing for hemochromatosis worthwhile? 
Eur J Epidemiol 2004; 19:101-109. 
o Wu J, Alizadeh BZ, Veen TV, Meijer JW, Mulder CJ, Pena AS. Association of FAS (TNFRSF6)-
670 gene polymorphism with villous atrophy in coeliac disease. W J Gastroenterol 2004; 
10:717-20. 
o Malekzadeh R, Sotoudeh M, Derakhshan MH, Mikaeli J, Yazdanbod A, Merat S, Yoonessi A, 
Tavangar M, Abedi BA, Sotoudehmanesh R, Pourshams A, Asgari AA, Doulatshahi S, Alizadeh 
BZ, Arshi S, Madjidpoor A, Mir Moomen S, Fleischer DE. Prevalence of gastric precancerous 
lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of 
Iran. J Clin Pathol 2004; 57:37-42. 
o Linskens RK, Mallant-Hent RC, Murillo LS, von Blomberg BM, Alizadeh BZ, Pena AS. Genetic 
and serological markers to identify phenotypic subgroups in a Dutch Crohn' s disease 
population. Dig Liver Dis 2004; 36:29-34 
 
 
 
 
 
 
 171
2003 
o Gasche C, Alizadeh BZ, Pena AS. Genotype-phenotype correlations: how many disorders 
constitute inflammatory bowel disease? Eur J Gastroenterol Hepatol 2003; 15:599-606. 
o Njajou OT, Alizadeh BZ, van Duijn CM. Genetic screening for common mutations: lessons 
from hereditary hemochromatosis. Eur J Epidemiol 2003; 18:3-4.  
o Zur Hausen A, Crusius JB, Murillo LS, Alizadeh BZ, Morre SA, Meijer CJ, van den Brule AJ, 
Pena AS. IL-1B promoter polymorphism and Epstein-Barr virus in Dutch patients with gastric 
carcinoma. Int J Cancer 2003; 10:866-7. 
2002 
o Njajou OT, Alizadeh BZ, Vaessen N, Vergeer JM, Houwing-Duistermaat JJ, Hofman A, Pols 
HAP, Van Duijn CM. The role of hemochromatosis C282Y and H63D gene mutations in type 2 
diabetes: findings from the Rotterdam Study and meta-analysis. Diabetes Care 2002; 
25:2112-3. 
o Murillo L, Crusius JB, van Bodegraven AA, Alizadeh BZ, and Pena AS. CARD15 gene and the 
classification of Crohn's disease. Immunogenetics 2002; 54:59-61. 
o Van der Paardt M, Crusius JB, Garcia-Gonzalez MA, Baudoin P, Kostense PJ, Alizadeh BZ, 
Dijkmans BA, Pena AS, van der Horst-Bruinsma IE. Interleukin-1 beta and interleukin-1 beta 
receptor antagonist gene polymorphisms in ankylosing spondylitis. Rheumatology 2002; 
41:1419-23. 
≤2001 
o Sotoudehmanesh R, Malekzadeh R, Massarrat S, Fazel A, Alizadeh BZ, Eshraghian MR. A 
randomized controlled comparison of three quadruple therapy regimens in a population with 
low H.pylori eradication rates. J Gastroenterol & Hepatol 2001; 16:264-68. 
o Fakheri H, Malekzadeh R, Merat Sh, Khatibian M, Fazel A, Alizadeh BZ, Massarrat S. 
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of 
Helicobacter pylori in a population with a high Metronidazole resistance rate. Aliment 
Pharmacol & Ther 2001; 15:411–16. 
o Kaviani MJ, Malekzadeh R, Vahedi H, Amini M, Kamalian N, Sotoudehmanesh R, Zare R, 
Massarrat S, Alizadeh BZ. Various duration of standard regimen (amoxicillin, metronidazole, 
colloidal bismuth sub-citrate for 2 weeks and with additional ranitidine for 1 or 2 weeks) on 
eradication of Helicobacter pylori in peptic ulcer Iranian patients. A randomized single blind 
prospective controlled trial. European Journal of Gastroenterology & Hepatology 2001 
(accepted). 
o Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian MR, Vakili A, Saghari 
M & Massarrat S. Furazolidone versus metronidazole in quadruple therapy for eradication of 
Helicobacter pylori in duodenal ulcer disease. Alment & Phormacol Ther 2000; 14: 299-303.  
Publications in Iranian Academic Journals 
o Mikaeli J, Malekzadeh R, Alizadeh BZ, Nasseri Moghaddam S, Valizadeh S, Khoncheh R,  
Massarrat S. Prevalence of Helicobacter pylori in two Iranian Provinces with high and low 
incidence of gastric carcinoma. Archives of Iranian Medicine (official English journal of the 
Academy of Medical Science of Iran,) 2000; 3:6-9 (Abstract: Gastrenterol;1999; 116:G1108). 
o Alizadeh BZ, Taheri H, Malekzadeh R, Ansari R, Khatibian M, Ebraheemi Daryanee N. The 
etiology of chronic hepatitis in Iran, a multi center cross sectional study. Govaresh (official 
journal of Iranian Society of Gastroenterology & Hepatology) 1999; 13&14:13-23. 
o Ansari R, Malekzadeh R, Mikaeli J, Tabib M, Khatibian M and Alizadeh BZ. A comparative 
study of paracentesis of massive ascites in cirrhotic patients with and without using IV 
Albumin. Journal of faculty of Medicine; (The journal of Tehran University of Medical Sciences) 
1998; 6:11-6 (Abstract: Gastroenterol 1999; 116:L0025). 
 172
o Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian R, Vakeli A, Saghari 
M. Effect Furazolidone vs Metronidazole in helicobacter pylori eradication. Govaresh (official 
journal of Iranian Society of Gastroenterology & Hepatology) 1999; 13 & 14:8-11. 
o Sotudehmanesh R, Malekzadeh R, Massarrat S, Alizadeh BZ, Eshraghian M. Comparing 
replacement of metronidazole rather than prolongation of treatment duration in quadruple 
therapy for Hp eradication. Govaresh (official Journal of Iranian Society of Gastroenterology & 
Hepatology), 1999; 3:142-5. 
o Zahedi MJ, Malekzadeh R, Amini M, Khatibian M, Soleimani MH, Vahedi H, Alizadeh BZ, 
Saghari M, Siavoshi F. Helicobacter pylori recurrence after successful eradication, one year 
follow up in Iran. Digestion 1998, 59:Exhb 3233. 
o Mikaeli J, Malekzadeh R, Ansari R, Khatibian M, Alizadeh BZ, Daneshvar C, Siavoshi F. Result 
of triple therapy in eradication of Helicobacter pylori and duodenal ulcer healing. Scientific 
Journal of Medical Council of I.R. Iran 1998; 16; 4:265-70. 
o Mikaeli J, Malekzadeh R, Khatibian M, Vahedi H, Ansari R, Soleimani H and Alizadeh BZ. 
“Graded pneumatic dilatation without fluoroscopy in treatment of achalasia”. Medical Journal 
of the Islamic Republic of Iran, In press (Abstract: Gastrointest Endo 1997; 45:201.) 
o Mikaeli J, Khatibian M, Ansari R, Malekzadeh R, Alizadeh BZ. Endoscopic sprotrotomy in 
treatment of post surgical complication of Cholecystectomy. Research in Medicine (official 
journal of Beheshtee University of Medical Sciences); (Accepted) 
o Yousefi-Rad M, Malekzadeh R, Khatibian M, Alavian SM, Rezvan R, Kamalian N, Alizadeh BZ. 
Prospective controlled trial of interferon alpha (INE) in Iranian patients with chronic hepatitis. 
Gastroenterol 1997; 112:A1420. 
o Malekzadeh R, Amini M, Mikaeli J, Vakili A, Siavoshi F, Kashifard M, Alizadeh BZ. Six months 
reinfection rate in helicobacter pylori positive acid peptic disease in Iranian patients after 
eradication.  Gastroenterol 1997; 112:A207. 
o Khoshkholgh M, Saberi Firoozi M, Farahi M, Siavoshi F, Khatibian M, Vahedi H, Mikaeli J,  
Ansari R, Alizadeh BZ, Malekzadeh R,  Massarrat S. Total pepsin activity and gastrin in sera 
as markers of eradication of helicobacter pylori. Iranian Journal of Medical Science, 1994; 
19:106-08 (In English) 
o And more than 10 other abstracts of scientific works presented in Iranian national congresses. 
 
 

